Cancer Letters 410 (2017) 124-138

Contents lists available at ScienceDirect

Cancer Letters

journal homepage: www.elsevier.com/locate/canlet

Mini-review

The convergent roles of the nuclear factor I transcription factors in development and cancer

Kok-Siong Chen^a, Jonathan W.C. Lim^a, Linda J. Richards^{a, b, *}, Jens Bunt^{a, *}

^a Queensland Brain Institute, The University of Queensland, Brisbane 4072, Australia
 ^b The School of Biomedical Sciences, The University of Queensland, Brisbane 4072, Australia

ARTICLE INFO

Article history: Received 4 July 2017 Received in revised form 11 September 2017 Accepted 16 September 2017

Keywords: Nuclear factor one Nuclear factor I NFI Transcription factor Development Tumorigenesis

ABSTRACT

The nuclear factor I (NFI) transcription factors play important roles during normal development and have been associated with developmental abnormalities in humans. All four family members, NFIA, NFIB, NFIC and NFIX, have a homologous DNA binding domain and function by regulating cell proliferation and differentiation via the transcriptional control of their target genes. More recently, *NFI* genes have also been implicated in cancer based on genomic analyses and studies of animal models in a variety of tumours across multiple organ systems. However, the association between their functions in development and in cancer is not well described. In this review, we summarise the evidence suggesting a converging role for the *NFI* genes in development and cancer. Our review includes all cancer types in which the *NFI* genes are implicated, focusing predominantly on studies demonstrating their oncogenic or tumours suppressive potential. We conclude by presenting the challenges impeding our understanding of NFI function in cancer biology, and demonstrate how a developmental perspective may contribute towards overcoming such hurdles.

© 2017 Elsevier B.V. All rights reserved.

Introduction

Cancer is driven by a series of acquired features that facilitate the initiation and progression of tumorigenesis by deregulating cellular proliferation and differentiation [1]. These features are acquired as a consequence of changes in gene expression, compromising physiological pathways that are normally regulated to ensure the function and maintenance of mature cellular phenotypes and optimal organ system performance. Not surprisingly, many pathways that are mis-regulated in cancer also function during normal development to control the rapid growth and development of each organ system [2]. Normal biological processes important for development, such as cellular proliferation, differentiation, and migration, are often compromised in cancer. As such, transcription factors that normally regulate these processes in development are often disrupted during tumorigenesis, either by direct mutation, or indirectly through chromosomal translocation. The pathways regulated by these transcription factors can be associated either with paediatric tumours during development or with adult cancers which result from mutations that revert mature cells to a developmental phenotype that enables rapid proliferation. In the last decade, genomic analyses and studies in mouse models have implicated such transcription factors in a variety of tumours across multiple organ systems.

The NFI, or CCAAT box-binding transcription factor (CTF), family of genes was first described for its role in stimulating the initiation of adenovirus DNA replication. It was later found to play important roles in transcriptional regulation, particularly during development [3]. The NFI family consists of four transcription factors in humans and most vertebrates: NFIA, NFIB, NFIC, and NFIX [4]. These share a highly conserved DNA-binding domain at their N-termini, and therefore bind to a common DNA sequence [5,6] (Fig. 1). The C-termini of the NFI protein family demonstrate greater divergence, which is further compounded by the existence of multiple splice sites [7–11] and post-translational modifications [12–16]. Consequently, each NFI transcription factor encodes multiple splice variants, although the functions of many of these remain unknown.

NFI transcription factors regulate cell proliferation and differentiation during the development of multiple organ systems, including the central nervous system (CNS) [17–23], mammary gland [24], and lungs [18,25] (Fig. 2). These transcription factors are also required to drive hematopoiesis [26–31], osteoblastosis





CANCER

氘

^{*} Corresponding authors. E-mail addresses: richards@uq.edu.au (LJ. Richards), j.bunt@uq.edu.au (J. Bunt).



Fig. 1. Schematic representations of the structural variability of the NFI transcription factors. Each exon is represented relative to its total amino acid length. All NFI family members share a highly conserved DNA-binding and dimerization domain at their N-termini (green box). The exon 1 region is variable due to alternative transcriptional start sites. The C-termini of the NFI proteins vary between family members and also between isoforms. Variants with similar structure, differing only in exon 1 are represented with a single variant. Boxes that have been lightly coloured represent exons with alternative reading frames within the same exonic region. Commonly detected phosphorylation and acetylation sites are portrayed in this figure [208]. Variants with corresponding ENSEMBL spliced transcript ID adopted from GENCODE v24 [214] are outlined in Supplementary Table 1. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

NF	IA	NF	-IX	NFIB		
Role in development	Role in cancer	Role in development Role in cancer		Role in development	Role in cancer	
Brain		Brain		Brain		
Driver of astroglial differentiation	TSG/oncogene in astrocytoma	Driver of astroglial differentiation	Oncogene in astrocytoma	Driver of astroglial differentiation	TSG in astrocytoma	
Astroglial-oligodendroglial	TSG in oligodendroglioma			Salivary gland		
cell fate determinant and				Driver of submandibular	TSG in AdCC	
maintains mature				gland tubule cell		
oligodendrocytes		_		differentiation		
Driver of postmitotic CGN	TSG in medulloblastoma	Brain		Lung		
differentiation			5	Driver of mesenchymal-to-	TSG in NSCLC	
Bone marrow		Salivary		epithelial differentiation		
Lineage fate determinant	TSG in excessive	dand _		and maintains epithelial		
that favours the	erythroblastosis-type of	giand 1	Mammary	cells		
megakaryocyte-erythroid	myeloproliferative		dland	Mammary gland		
lineage progression over	disorders, acute erythroid			Transcriptional regulator of	Oncogene in ER-negative	
granulocyte-monocyte	leukemia, and T-cell	\times	$\parallel \rightarrow$	mammary-specific	breast carcinoma	
lineage progression	lymphomas			proteins, but no known		
				function in mammary		
NF	FIC	Bone	$\square \square$	gland epithelial cell differentiation.		
Role in development	Role in cancer			Skin		
Mammary gland				Maintains melanocyte	Oncogene/TSG in	
Driver of epithelial cell	TSG in ER-positive and		$ \leq 1 $	stem cell quiescent state	cutaneous melanoma	
differentiation and/or	ER-negative breast		Skin		Oncogene in uveal	
apoptosis, but no known	carcinomas				melanoma	
function in maintaining the			\sim $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$	Bone marrow		
differentiated cell state				Driver of megakaryocyte	TSG in excessive	
Bone				differentiation from	erythroblastosis-type of	
Regulator of osteoblast	TSG in osteosarcoma			megakaryocyte-erythroid	myeloproliferative disorders	
proliferation,				progenitors	and T-cell lymphomas	
differentiation, and		-	Bono morrow	Bone		
migration			Bone marrow	Regulator of osteoblast	TSG in osteosarcoma	
Bone marrow			'	proliferation,		
Driver of megakaryocyte	TSG in T-cell lymphomas			differentiation, and		
differentiation from				migration		
megakaryocyte-erythroid						
progenitors						

Fig. 2. Organ systems in which the NFI genes are implicated, both during development and in cancer. During development, the NFI transcription factors are important for cell proliferation, differentiation, migration and lineage progression. These genes are also reported to function as oncogenes or tumour suppressor genes (TSG) in cancer, depending on the cellular and molecular contexts.

[32–34] and melanocytosis [35,36] (Fig. 2). However, NFI deregulation can lead to uncontrolled cell proliferation or a failure to differentiate, and could therefore potentially contribute to tumour growth. In this review, we describe the oncogenic and tumoursuppressive potential of the NFI transcription factors and discuss what is known about the function of these genes in various types of cancer, in the context of their function in these same organ systems during development (Fig. 2).

Central nervous system tumours

Glioma

In astrocytomas, high expression levels of NFIA [37] and NFIB [38] correlate with better clinical outcome (Table 1). For example, a high level of NFIA mRNA in adult grade IV glioblastoma (GBM) and paediatric grade III-IV astrocytomas is associated with improved survival [37] (Table 1). Similarly, high NFIB expression correlates with better overall survival probability in GBM, grade II-IV astrocytomas, and gliomas in general [38] (Table 1). Higher-grade tumours are associated with lower NFIA [37] and NFIB [38] mRNA expression levels (Table 1). The percentage of cells that express NFIA protein, as detected by immunohistochemistry, is also reduced in higher-grade astrocytomas [37] (Table 1). These findings suggest that NFIA and NFIB function as tumour suppressors. This is corroborated by the identification of insertions that affect the NFI transcription factors in multiple insertional mutagenesis mouse models designed to identify genes involved in glioma tumorigenesis [39-41] (Table 2a). Notably, insertions within Nfic and *Nfix* have also been identified in these mouse models [41] (Table 2a), suggesting that NFIC and NFIX may also function as tumour suppressors in glioma.

Genomic aberrations affecting NFIB are observed in approximately 40% of human astrocytomas, mainly as loss of heterozygosity (LOH) due to large deletions of chromosome 9p, which harbours other tumour suppressors such as CDKN2A [42-46]. Furthermore, NFIB overexpression induces cell differentiation and inhibits growth in GBM tumours, an outcome which is mediated by STAT3 signalling [38]. This implies that NFIB functions as an essential driver of glial differentiation in glioma. Its disruption results in the failure of tumour cells to differentiate, inevitably contributing to sustained cell proliferation. This scenario reflects NFI function in the developing brain, where disruption of Nfia, Nfib, and Nfix results in reduced and delayed differentiation of glial cells, causing progenitor cells to remain in a proliferative state [17–23]. During prenatal development, NFIA and NFIB are expressed within neural progenitor cells that give rise to various glial and neuronal cell populations throughout the brain and spinal cord [47–49]. The high expression of these genes persists in both progenitor and differentiated cells of the adult brain, although their function in this case remains unknown [50]. Nevertheless, their reduced expression in high-grade gliomas suggests that disruption of NFI activity is important in gliomagenesis [37,38] (Table 1).

Besides its potential role as a tumour suppressor, NFIA is also likely to act as a glioma type determinant. The percentage of NFIAexpressing cells in oligodendroglioma samples is consistently lower than in astrocytoma [37] (Table 1). Within the mRNA expression data of mixed glioma samples, low *NFIA* expression is associated

Table 1

	Association of NFI exi	pression with human	tumour subtype.	progression.	cell characteristics.	and res	ponse to treatment.
--	------------------------	---------------------	-----------------	--------------	-----------------------	---------	---------------------

Tumour Type	NFI Member	Association	Findings	Reference
Bladder cancer	NFIA	Tumour progression	Elevated NFIA mRNA expression is associated with T1 progressive	Sharron Lin et al., 2014
	NFIB	Response to treatment	bladder cancer, compared with 11 nonprogressive tumours. High <i>NFIB</i> mRNA expression is associated with oxaliplatin resistance in	[143] Kashiwagi et al., 2011
Breast cancer	NFIB	Response to treatment	bladder cancer. High <i>NFIB</i> mRNA expression in primary breast cancer tumour samples is associated with a good pathologic response to neoadjuvant	[144] Oh et al., 2014 [145]
Breast cancer (ER-negative)	NFIB	Response to treatment	chemotherapy. High <i>NFIB</i> mRNA expression in ER-negative breast cancer tumour samples is associated with a good pathologic response to taxane-	Hatzis et al., 2011 [99]
		Subtype	anthracycline chemotherapy. High <i>NFIB</i> mRNA expression is associated with ER-negative subtype of breast cancer	Moon et al., 2011 [95], Smith et al. 2008 [06]
Colorectal cancer	NFIB	Response to treatment	High <i>NFIB</i> mRNA expression is associated with oxaliplatin resistance in colorectal cancer.	Kashiwagi et al., 2008 [90]
	NFIX	Response to treatment	NFIX expression is associated with chemotherapy resistance in colorectal cancer patients.	Hu et al., 2016 [146]
Embryonal tumours with multilayered rosettes	All NFI members	Subtype	Low mRNA expression of NFI transcription factors is associated with <i>C19MC</i> amplified/LIN28+ embryonal tumours with multilayered	Spence et al., 2014 [147]
Epithelial ovarian cancer	NFIB	Response to treatment	High <i>NFIB</i> mRNA expression is associated with a good pathologic response to chemotherapy.	Liu et al., 2012 [148], Spentzos et al., 2005
Giant cell tumour of bone	NFIB	Tumour progression	Elevated <i>NFIB</i> mRNA expression is associated with metastatic giant cell tumour of bone samples.	[149] Mosakhani et al., 2013 [150], Quattrini et al., 2015 [151]
Glioma Astrocytoma	NFIA	Cell characteristics	<i>NFIA</i> is a transcriptional signature of a stemlike compartment in single-	Patel et al., 2014 [152]
		Grade Survival	Low <i>NFIA</i> mRNA expression is associated with increased tumour grade. High <i>NFIA</i> mRNA expression is associated with better progression-free	Song et al., 2010 [37] Song et al., 2010 [37]
	NFIB	Cell characteristics	NFIB is a transcriptional signature of a stemlike compartment in single- cell transcriptional profiles of primary gliphastoma tumours	Patel et al., 2014 [152]
		Grade	Low <i>NFIB</i> mRNA expression is associated with increased tumour grade.	Stringer et al., 2016
		Survival	High <i>NFIB</i> mRNA expression is associated with better overall survival in patients with high-grade astrocytomas.	Stringer et al., 2016
		Subtype	Low NFIB mRNA expression is associated with mesenchymal subtype of glioblastoma.	Stringer et al., 2016 [38]
Astrocytoma (paediatric)	NFIB	Subtype	<i>NFIB</i> protein and mRNA expression is higher in anaplastic pilocytic astrocytoma (PA), compared with sporadic PA and NF1-PA. No strong	Ho et al., 2013 [153]
Oligodendroglioma	NFIA	Glioma subtype	<i>NFIB</i> expression is observed in diffuse glioma and non-neoplastic brain. The percentage of NFIA-expressing cells in oligodendrogliomas is consistently lower than in astrocytomas.	Song et al., 2010 [37]
Hepatocellular carcinoma	NFIB and	Subtype	Low <i>NFIA</i> mRNA expression is associated with oligodendrogliomas. High <i>NFIB</i> and <i>NFIC</i> mRNA expression is associated with hepatocellular	Sun et al., 2014 [51] Hoshida et al., 2009
Melanoma	NFIA	Tumour progression	Low NFIA expression is associated with metastatic melanoma, compared with primary tumours	[154] Kauffmann et al., 2008 [155]
	NFIB	Tumour progression	Lowered NFIB expression is associated with metastatic melanoma, compared with primary tumours.	Jaeger et al., 2007 [156]
Oropharyngeal squamous cell carcinoma	NFIA	Response to treatment	Disruption of NFIA is associated with irresponsiveness to therapy.	Walline et al., 2016 [157]
Osteosarcoma	NFIB	Tumour progression	Lowered NFIB expression due to single nucleotide polymorphism is associated with increased osteosarcoma metastasis.	Mirabello et al., 2015 [133]
Small cell lung cancer	NFIB	Subtype	High expression or amplification of <i>NFIB</i> was observed in both human and mouse primary small cell lung cancer tumours and cell lines.	Dooley et al., 2011 [85], Iwakawa et al., 2013 [86]
Uveal melanoma	NFIB	Tumour progression	Lowered <i>NFIB</i> mRNA expression is associated with aggressive class 2 uveal melanomas.	Onken et al., 2006 [158]

with oligodendrogliomas and the enrichment of oligodendrocytic genes [51] (Table 1). Loss of *NFIA* as part of chromosome 1p31 also correlates with oligodendroglioma [52–54]. Furthermore, NFIA overexpression in a mouse model of oligodendroglioma resulted in tumours that resemble astrocytoma, suggesting a direct role for NFIA in regulating glioma subtype specificity [55].

The role of NFIA as a cell fate determinant appears to be conserved during CNS development. For instance, down-regulation of *NFIA* favours the oligodendroglial lineage in the developing spinal cord [55]. In addition, both NFIA and NFIB play an essential

role in generating astrocytes from human fibroblasts *in vitro* [56]. Interestingly, NFIA expression appears to be required for the later stages of oligodendroglial differentiation during postnatal brain development [57]. In the adult neocortex, NFIA is more highly expressed in oligodendroglia than NFIB and NFIX, suggesting a role in maintaining oligodendroglial differentiation [50]. Therefore, while NFIA and NFIB have a tumour-suppressor role in astrocytoma, loss of NFIA could potentially contribute to oligodendroglioma in two ways, first as a glioma type determinant, and secondly by enhancing oligodendroglioma growth.

Table 2

The NFI transcription factors are implicated in multiple mouse models of cancer.

a. Insertional mutagenesis mouse models identifying common insertion sites within the Nfi loci									
Tumour type		Number of	Numb	er of obs	erved ins	ertions	Frequency (%)	Reference	
		tumours analysed	Nfia	Nfib	Nfic	Nfix	-		
Breast cancer									
Triple negative		39	12	13		5	≥33%	Rangel et al., 2016 [159]	
Breast cancer		33	1	13		1		Suarez-Cabrera et al., 20	17 [160]
Invasive lobular breast	carcinoma	99				8 ^a	8%	Kas et al., 2017 [161]	
Colorectal cancer		446	50	65			22%	March et al., 2011 [162]	
		17	>1 ^b	>1			>12%	Takeda et al. 2015 [163]	
		31	>1 ^b	>1			>6%	Takeda et al. 2015 [163]	
		37	>1 ^b	>1			>5%	Takeda et al. 2015 [163]	
Glioma		57							
Glioblastoma		6	1	1			33%	Vyazunova et al 2014	91
Non-glioblastoma		3 27	2	•			7%	Vyazunova et al. 2014	[9] Bender et al 2010 [40]
Mixed		108	1	1	1	5	7%	Johansson et al. 2004 [4	
Henatocellular carcino	m 1	228	174 ^b	1/1	1	25	>76%	Bard-Chappan et al. 2004 [4	1 1 [164]
hepatocential carcinol	IIId	106	25	26		25	≥70% >22%	Kodama et al. 2016 [165	+ [104]
		100	17	20			255%	Kodama et al. 2016 [165	1
Lionata collular manager	ما بيان م ما بيا م	40	1/	ab		h	33% 10%		1
Laulannia	plastic notule	08	5	4		Z	10%	Kelig et al., 2009 [100]	16 [167]
Leukenna		467	/	3			15%	Heitemes-Harris et al., 20	
Lympnoma	1 .1 .	467	9	6			2%	Kool et al., 2010 [165], U	ren et al., 2008 [166]
Malignant peripheral n	herve sheath tumour	106	9	6			13%	Rahrmann et al., 2013 [1	36]
Medulloblastoma (SHH	l subtype)	85	220	- 2		18	47%	Genovesi et al., 2013 [58	
		41	220	7ª		_	59%	Lastowska et al., 2013 5	9]
		139	51	27		8	\geq 37%	Wu et al., 2012 [60]	
Melanoma		278	9				35	Perna et al., 2015 [130]	
		43		1			2%	de la Rosa et al., 2017 [1	58]
		82		1			1%	de la Rosa et al., 2017 [1	58]
Neurofibroma		269	55	40			31%	Rahrmann et al., 2013 [1	36]
Osteosarcoma		119		17 ^b			11%	Mirabello et al., 2015 [13	3]
		23		1			4%	Moriarity et al., 2015 [13	4]
		14		1		1	14%	Temiz et al., 2016 [169]	
Pancreatic ductal aden	ocarcinoma	198	26	44			≥22%	Perez-Mancera et al., 202	2 [170]
		42		7			17%	Mann et al., 2012 [171]	
Prostate cancer		45		1			2%	de la Rosa et al., 2017 [1	58]
		82	1	1			2%	de la Rosa et al., 2017 [1	58]
Thymic lymphoma		101	3	2	1		6%	Berquam-Vrieze et al., 20	011 [121]
b. Transgenic mouse m	nodels with observed	copy number altera	ations ir	n Nfi					
Tumour type	Number of t	umours analysed	Num	nber of of	oserved co	opy num	ber gain	Frequency (%)	Reference
			Nfia		Nfib	Ni	fic Nfix		
Ducatata and and					40			00%	Zhou et al. 2000 [472]
Prostate cancer 5 Small cell lung carcinoma 17				4 ^c 4 ^c			80% 24%	Zhou et al., 2006 [172] Dooley et al., 2011 [85]	
c. Correlation of NFI ex	c. Correlation of NFI expression level with tumour latency, metastasis, and median survival in transgenic mouse models with altered NFI expression								
Tumour type NFI member Alteration of				Finding				1	Reference
rumour type	NPI member	expression level		Findings				1	Celefence
Medulloblastoma	Nfia ^b	Reduced expression	n	Mice wi	th reduce	d expres	sion of Nfia dem	onstrated a	Genovesi et al., 2013 [58]
				significa	nt decrea	se in tun	nour latency.		
Small cell lung	Nfib ^a	Overexpression	Mice with overexpression of Nfib demonstrated a significant Se				Semenova et al., 2016 [88]		
carcinoma		decrease in tumour latency and more extensive metastasis.				nsive metastasis.			
Nfib ^a Overexpression Mice with overexpression of Nfib demonstrated a significant Wu et al., decrease in median survival				Wu et al., 2016 <mark>[89]</mark>					

 \geq Based on publication precise number is unknown, but minimal number represented.

^a Predicted as oncogene by the authors.

^b Predicted as tumour suppressor gene by the authors.

^c Correlation of NFI expression level with tumour latency, metastasis, and median survival in transgenic mouse models with altered NFI expression.

Medulloblastoma

Various mouse models have demonstrated that loss of *NFI* also contributes to tumour initiation and progression in medulloblastoma. The *Nfi* loci have been identified as common insertion sites in insertional mutagenesis mouse models of medulloblastomas of the Sonic Hedgehog (SHH) subgroup [58–60] (Table 2a). Since many of these insertions are shared between the primary tumour and metastases, it is likely that insertions within the *Nfi* loci represent early events that contribute to tumorigenesis or tumour progression [60]. This role has been corroborated in a mouse model of SHH

medulloblastoma with heterozygous loss of *Nfia* [58] (Table 2a). In these mice, reduced *Nfia* expression results in higher tumour incidence and decreased tumour latency [58]. These findings suggest that NFIA acts as a tumour suppressor of SHH-medulloblastoma.

The role of *Nfi* in the postmitotic differentiation of cerebellar granule neurons (CGNs), the cell type that gives rise to SHH-medulloblastomas [61], has been extensively studied [62–65]. During postnatal cerebellar neurogenesis, mature CGNs within the internal granule cell layer (IGL) strongly express the NFI transcription factors, including NFIA and NFIB [62,66]. *Nfia* deletion in mice disrupts postmitotic CGN differentiation within the IGL

[62.64]. Thus, the defective differentiation of CGNs due to the loss of NFIA could contribute to the initiation of SHH-medulloblastoma [58] (Table 2a). Although the role of NFIB in postmitotic CGN differentiation has not been investigated as Nfib knockout mice die perinatally, defects in CGN development were reported at embryonic day 18 [18]. Given that NFIB expression is elevated in mature CGNs [62], it is likely that loss of *NFIB* also contributes to the initiation of SHH-medulloblastoma. It should be noted, however, that the role of NFI in medulloblastoma could be molecular context-dependent. No Nfi insertions were reported in another insertional mutagenesis mouse model with Tp53 deletion [60]. Overall, the role of the NFI transcription factors in medulloblastoma highly correlates with their role in development. These findings suggest that further study of the NFI genes and the pathways that they regulate during cerebellar and hindbrain development may be useful for understanding and treating these tumour types.

Carcinomas

Adenoid cystic carcinoma

The NFI transcription factors, particularly NFIB, appear to play a prominent role in various carcinomas, including adenoid cystic carcinoma (AdCC), breast carcinoma, and lung carcinoma (Table 3). In AdCC, *MYB-NFIB* fusion, or a similar fusion event affecting the *MYB* homologue, *MYBL1*, is found in 50% of tumours [67–76] (Table 3). This frequent fusion event is regarded as a molecular hallmark of AdCC [70,75,77]. Interestingly, this event always involves *MYB* fusing to the 3' end of the *NFIB* locus, suggesting that preservation of this region is critical for AdCC tumorigenesis [68,69,73]. Indeed, it was recently reported that this fusion event allows *NFIB* enhancers to drive *MYB* expression, thereby establishing a positive feedback loop that sustains expression of the oncogenic MYB protein [78].

Although increased expression of *MYB* or *MYBL1* is crucial to AdCC tumorigenesis, NFIB is likely to play an independent role as a tumour suppressor. All reported *MYB-NFIB* translocations disrupt the *NFIB* coding sequence [68,69,73] and independent fusion events between *NFIB* and other fusion partners have been reported [70,79–81] (Table 3). Moreover, the detection of truncating mutations and homozygous deletion of *NFIB* have also been identified in AdCC [70,75,78,82]. These findings warrant further investigation of NFIB function in AdCC, particularly in cases where *MYB* or *MYBL1* expression is unaffected.

Although the role of NFIB in salivary gland development has not been well studied, *Nfib* knockout mice display defects in terminal tubule formation and tubule cell differentiation during submandibular gland development [83]. Given that AdCC arises from epithelial cells of the secretory glands, most commonly the salivary glands of the head and neck [84], understanding the role of NFIB in salivary gland development could contribute to our understanding of how its loss is involved in AdCC. We speculate that the disruption of NFIB caused by the *MYB-NFIB* translocation perturbs epithelial cell differentiation, maintaining the proliferative state of these cells and thereby promoting AdCC tumorigenesis.

Lung carcinoma

In contrast to its potential tumour suppressor role in AdCC, NFIB appears to promote tumorigenesis in small cell lung cancer (SCLC). High expression or amplification of *NFIB* has been reported in both human and mouse primary SCLC tumours and cell lines, suggesting that NFIB functions as an oncogene in this tumour type [85,86] (Table 1). Indeed, overexpression of NFIB promotes tumour initiation and metastatic progression in mouse models of SCLC *in vivo*

[87–89] (Table 2b and c). One underlying mechanism involves NFIB binding to chromatin and increasing its accessibility at distal regulatory elements that regulate pro-metastatic protein expression [87]. *NFIB* expression is also associated with increased cell proliferation in SCLC cell lines *in vitro* [85], whereas its knockdown induces the opposite phenotypes: reduced proliferation, and increased apoptosis and senescence [85,89].

The role of NFIB as an oncogene in lung carcinoma appears restricted to SCLC. In squamous cell carcinoma, no correlation was observed between NFIB expression and clinical outcome [90], while NFIB down-regulation is associated with poor clinical outcome and increased aggressiveness in non-small cell lung carcinoma (NSCLC) (Table 1). Contrary to its role as a prometastatic oncogene in SCLC, NFIB is down-regulated during epithelial-to-mesenchymal transition (EMT) in a NSCLC cell line *in vitro* [91]. Coincidentally, mesenchymal-to-epithelial transition (MET), a process that normally occurs during lung development, is disrupted in the lungs of Nfib-deficient mice [18]. Specifically, the differentiation of type I and II epithelial cells is defective and the lung mesenchyme is thickened due to the increased number of mesenchymal cells [18]. Defective MET resulted in defects in lung maturation, causing Nfib-deficient mice to die at birth [18,25]. These findings suggest that NFIB is essential for driving mesenchymal-to-epithelial differentiation during lung development, and that it may also be required for epithelial cell maintenance following development. Consequently, loss of NFIB may play a role in the EMT of differentiated epithelial cells and epithelial stem cells in NSCLC [92], contributing to the development of these tumours. As SCLC arises from lung neuroendocrine cells [93], further studies are required to determine whether NFIB is required for the development of these cells, and how this process is maladapted in SCLC.

Breast carcinoma

Overexpression or amplification of NFIB is a common feature of oestrogen receptor (ER)-negative breast carcinoma [94–98] (Table 1). Microarray analyses have demonstrated that NFIB expression is a predictor of extensive residual disease following taxane-anthracycline chemotherapy in ER-negative breast cancer [99]. As such, NFIB expression may be associated with cancer aggressiveness in this tumour type, with NFIB knockdown in vitro being shown to reduce proliferation in ER-negative breast cancer cells [95], demonstrating its oncogenic potential. NFIC, on the other hand, may function as a tumour suppressor in breast carcinomas. Overexpression of the NFI-C2 isoform in an ER-negative breast cancer cell line inhibits cell proliferation and tumour growth [9]. A similar observation has been reported for NFIC in ER-positive breast cancer cells, in which NFIC knockdown resulted in increased proliferation and the expression of the CCND1 oncogene [100]. Thus, NFIB may function as an oncogene in ER-negative breast cancer, whereas NFIC functions as a tumour suppressor in both ER-positive and ER-negative breast cancers.

NFIB and NFIC play essential roles in various stages of mammary gland development [24]. These transcription factors are highly expressed in terminally differentiated mammary epithelial cells during mammary gland development [8,101], and are involved in the transcriptional regulation of mammary-specific proteins [14,101–111]. Deletion of *Nfib* from mammary stem cells and differentiating alveoli, however, appears to have little or no impact on cell differentiation in the mammary gland [112], indicating that NFIB may be redundant for epithelial cell differentiation. NFI-C2 expression in epithelial cells decreases at lactation and is restored at involution [113], suggesting that NFI-C2 could be required for epithelial cell differentiation and/or apoptosis but does not play a

Table 3Translocations of NFI in various tumours and cancer cell lines.

Tumour type	NFI	Fusion	Tumour location	Cases	Reference
Adenocarcinoma	NFIA	DCLK1	Breast cancer	1/1019	Yoshihara et al., 2015 [75]
		FAF1	Breast cancer	1/1019	Yoshihara et al., 2015 [75]
		FGGY	Breast cancer	1/1019	Yoshihara et al., 2015 [75]
		HYI	Breast cancer	1/1019	Yoshihara et al., 2015 [75]
		LTV1	Breast cancer	1/1019	Yoshihara et al., 2015 [75]
		ST6GALNAC3	Breast cancer	1/1019	Yoshihara et al., 2015 [75]
		EHF	Breast cancer ^b	1	Asmann et al., 2011 [173],
					Ha et al., 2011 <mark>[174]</mark> , Klijn
					et al., 2015 [175], Robinson
					et al., 2011 [176], Stephens
					et al., 2009 [177]
		ATG4C	Ovarian serous cystadenocarcinoma	1/400	Yoshihara et al., 2015 [75]
		INADL	Ovarian serous cystadenocarcinoma	1/400	Yoshihara et al., 2015 [75]
		CYP2J2	Prostate adenocarcinoma	1/178	Yoshihara et al., 2015 [75]
		ZNF253	Rectum adenocarcinoma	1	Yoshihara et al., 2015 [75]
	NFIB	HEATR5B	Breast cancer	1/1019	Yoshihara et al., 2015 [75]
		MYB ^a	Breast cancer	1/1019	Yoshihara et al., 2015 [75]
		MPDZ	Breast cancer	1/1019	Yoshihara et al., 2015 [75]
		SIRN ZDUUC21	Breast cancer	1/1019	Yoshihara et al., 2015 [75]
	NEC	ZDHHC21	Lung adenocarcinoma	1/487	Yoshihara et al., 2015 [75]
	NFIC	FZKI"	Breast cancer	2/1019	Yoshihara et al., 2015 [75]
			Breast cancer	1/1019	Yoshihara et al. 2015 [75]
		CELEE	Diedst Calicel	1/1019	Yoshihara et al. 2015 [75]
	NEIY	DAND5	Breast cancer	ı 2/1010	Voshihara et al. 2013 [75]
	INFIA	DANDS		2/1019	Voshihara et al. 2015 [75]
		MAST1 ^a	Breast cancer	1/407	Robinson et al. $2013 [75]$
		MCU	Breast cancer	1/1019	Voshihara et al. 2015 [75]
		TBCD	Breast cancer	1/1019	Yoshihara et al. 2015 [75]
		BSG	Breast cancer ^b	1	Edgren et al. 2011 [178]
		GCDH	Breast cancer ^b	1	Kliin et al. 2015 [175]
		Gebii	Lung adenocarcinoma	1/487	Yoshihara et al., 2015 [75]
		ANKRD40	Endocervical Adenocarcinoma	1	Yoshihara et al., 2015 [75]
Adenoid cystic	NFIB	MYB [#]	Breast	4/4	Persson et al., 2009 [73]
carcinoma			Breast	10/12	Martelotto et al., 2015 [179]
			Breast	2/4	Brill et al., 2011 [68]
			Breast	6/31	D'Alfonso et al., 2014 [180]
			Breast	12/13	Wetterskog et al., 2012 [181]
			Head and neck	7/7	Persson et al., 2009 [73]
			Larynx	2/5	Brill et al., 2011 [68]
			Salivary gland	21/30	Brill et al., 2011 [68]
			Salivary gland	18/37	West et al., 2011 [74]
			Salivary gland	59/91	Rettig et al., 2015 [182]
			Salivary gland	32/60	Ho et al., 2013 [70]
			Salivary gland	39/102	Mitani et al., 2016 [80]
			Salivary gland	12/25	Rettig et al., 2016 [79]
			Salivary gland	8/20	Brayer et al., 2016 [67]
				16/33	Fujii et al., 2017 [76]
			Siliolidsal Cavity Trachea/bronchus	ון כ 7/10	$\begin{array}{c} \text{Drift et al., 2011 [08]} \\ \text{Brill et al. 2011 [69]} \end{array}$
			Vulva	2/2	$\begin{array}{c} \text{DIII et al., 2011 [00]} \\ \text{Prill et al. 2011 [62]} \end{array}$
			Mix samples	3/8	Costa et al 2014 [60]
		MYBL1	Salivary gland	12/102	Mitani et al 2016 [80]
			Salivary gland	2/25	Rettig et al. 2016 [79]
			Salivary gland	3/20	Braver et al., 2016 [67]
			Salivary gland	2/33	Fujii et al., 2017 [76]
		AIG1	Salivary gland	1/102	Mitani et al., 2016 [80]
		MAN1A1	Salivary gland	1/60	Ho et al., 2013 [70]
		MAP3K5	Salivary gland	2/25	Rettig et al., 2016 [79]
		MYO6	Salivary gland	1/25	Rettig et al., 2016 [79]
		NKAIN2	Salivary gland	1/102	Mitani et al., 2016 [80]
		PTPRD	Salivary gland	1/102	Mitani et al., 2016 [80]
		RIMS1	Salivary gland	1/25	Rettig et al., 2016 [79]
		RPS6KA2	Salivary gland	1/25	Rettig et al., 2016 [79]
		XRCC4	Salivary gland	1/102	Mitani et al., 2016 [80]
Other	NFIA	SCP2	Non-small cell lung cancer ^b	1	Klijn et al., 2015 [175]
carcinomas	NFIB	FREM1	Lung squamous cell carcinoma	1/220	Yoshihara et al., 2015 [75]
	NFIC	C16ort55	Adrenocortical carcinoma	1	Yoshihara et al., 2015 [75]
		FZR1ª	Cervical squamous cell carcinoma	1	Yoshihara et al., 2015 [75]
		LSM/	Cervical squamous cell carcinoma	1	Yoshihara et al., 2015 [75]
		PIP5KIC ZNECE2		I 1/220	KIIJN ET AL., 2015 [1/5]
	NELV	LINF033	Lung squamous cell carcinoma	1/220	rusiiiidra et al., 2015 [75] Voshihara et al. 2015 [75]
	INFIA	MAST1 ^a	Esopilageal calcillollia Lung carcinoma ^b	1	10511111111111111111111111111111111111
		11/1/1/1/1	Lung Carcinoma	1	Mign Ct al., 2013 [1/3]

Table 3 (continued)

Tumour type	NFI	Fusion	Tumour location	Cases	Reference
		RALGPS1	Oral cavity squamous cell carcinoma	1	Yoshihara et al., 2015 [75]
			Head and neck squamous cell carcinoma	1/300	Yoshihara et al., 2015 [75]
		GATAD2A	Thyroid carcinoma	1/494	Yoshihara et al., 2015 [75]
Other cancers	NFIA	CBFA2T3	Acute erythroid leukemia	1	Micci et al., 2013 [116]
		NCOR1	Acute lymphoblastic leukemia	1/255	Liu et al., 2017 [183]
		RNLS	Glioblastoma	1/101	Frattini et al., 2013 [184]
				1/175	Shah et al., 2013 [185]
		AKD1	Medulloblastoma	1/79	Robinson et al., 2012 [186]
		TNNI3K	Melanoma	1/25	Berger et al., 2012 [127]
		RAF1	Pilocytic astrocytoma	1	Yde et al., 2016 [187]
	NFIB	C12orf42	Multiple myeloma	1/38	Chapman et al., 2011 [188]
	NFIC	CELF5 ^a	Low-grade glioma	1/266	Yoshihara et al., 2015 [75]
		BRAF	Melanoma	1/531	Kim et al., 2017 [129]
	NFIX	MAST1 ^a	Melanoma	1/25	Berger et al., 2012 [127]
		TNPO2	Melanoma	1/224	Cancer Genome Atlas, 2015 [189]
Benign tumours	NFIB	HMGA2	Lipoma	1	Pierron et al., 2009 [190]
			Lipoma	1/2	Nilsson et al., 2005 [138]
			Lipoma	2/29	Dadone et al., 2015 [191]
			Lipoma	2/5	Italiano et al., 2008 [137]
			Lipoma	1	Lacaria et al., 2017 [192]
			Pleomorphic adenoma	2/28	Asp et al., 2006 [193]
				2/2	Geurts et al., 1998 [139]
		MYB ^a	Dermal cylindroma	8/12	Fehr et al., 2011 [142]

^a Fusion partner was detected in more than one tumour type.

Cell line.

role in maintaining the differentiated cell state. Moreover, NFI-C2 up-regulates TP53 expression in the mammary gland during pregnancy [113]. Therefore, NFI-C2 likely functions as a protector against tumorigenesis during epithelial cell proliferation in mammary gland development.

Other carcinomas

Mis-regulation of the NFI transcription factors, or genomic aberrations that affect their gene loci, have also been observed in other carcinomas such as esophageal squamous cell carcinoma, hepatocellular carcinoma, and renal cell carcinoma (Tables 3 and 4). Based on current evidence, NFI transcription factors have both oncogenic and tumour suppressor potential, depending on the carcinoma type and its tissue of origin (Table 4). However, how the NFI transcription factors function in the development of these tissue types, and how this coincides with their role in carcinoma requires further investigation.

Hematopoietic tumours

Table 4

In the case of non-solid tumours, the NFI transcription factors have been implicated in hematopoietic tumours that include myeloproliferative neoplasms, leukemia, and lymphoma. Specifically, point mutations, focal deletions, and translocations of NFIA have been found in myeloproliferative neoplasms [114,115] and acute erythroid leukemia [116] (Table 3). Loss of NFIB due to 9p LOH was also reported in approximately 30% of myeloproliferative neoplasms [117–119], and in T-cell lymphomas (Sézary syndrome) [120]. These findings suggest a possible role for NFI in hematopoietic tumour development, as corroborated for T-cell lymphomas in an insertional mutagenesis mouse model where insertions within Nfia, Nfib and Nfic occur [121] (Table 2a).

During development, NFIA is an important regulator of hematopoiesis, particularly in lineage fate decisions. NFIA overexpression, coupled to induced differentiation, is associated with megakaryocyte-erythroid progenitor differentiation [26,27]. whereas its down-regulation is associated with granulocytemonocyte progenitor differentiation [27–29]. Low NFIA expression in cells committed to the granulocyte-monocyte lineage further drives these cells to undergo monocytic differentiation [30,31]. As a regulator of hematopoietic lineage commitment, disruption of NFIA could lead to the deregulation of hematopoiesis. One possible outcome of this is uncontrolled erythroblastosis [116], ultimately contributing to the development of acute erythroid leukemia or myeloproliferative neoplasms [114,115].

he putative roles of NFI in other carcinomas.						
Carcinoma type	NFI member	Proposed function				
Cutanaque equamous	NED	Tumour cupproce				

Carcinoma type	NFI member	Proposed function	Findings	Reference
Cutaneous squamous cell carcinoma	NFIB	Tumour suppressor	Down-regulation of NFIB is common in both cell lines and tumour samples, and drives tumour progression.	Zhou et al., 2015 [194], Zhou et al., 2014 [195]
Esophageal squamous cell carcinoma	NFIB	Oncogene	NFIB locus is amplified in primary tumours and cell lines.	Yang et al., 2001 [196]
Hepatocellular carcinoma	NFIA	Tumour suppressor	Copy number loss of NFIA has been reported in tumours.	Keng et al., 2009 [166], Fujimoto et al., 2012 [197]
	NFIB	Tumour suppressor	Copy number loss of NFIB has been reported in tumours.	Keng et al., 2009 [166], Fujimoto et al., 2012 [197]
		Oncogene	Knockdown of NFIB inhibits tumour cell growth and promotes apoptosis.	Zhang et al., 2015 [198]
Renal cell carcinoma	NFIC	Oncogene	Up-regulation of NFIC is observed in tumour cell lines.	Takaoka et al., 2011 [199]

NFIB and NFIC are also required to drive megakaryocyte differentiation from megakaryocyte-erythroid progenitors. NFIB expression is up-regulated during induced differentiation of megakaryocyte-erythroid progenitors [29], and megakaryocytes demonstrate increased expression of *NFIB* and *NFIC* [122,123]. Loss of *NFIB* or *NFIC* in megakaryocyte progenitors is sufficient to prevent their differentiation, whereas their overexpression increases cell maturation [124]. Therefore, the excessive erythroblastosis in polycythemia vera could be attributed to defective megakaryocyte differentiation as a consequence of loss of NFIB [117–119].

On the other hand, NFIX expression promotes myeloid lineage progression and suppresses lymphoid development in hematopoietic progenitors [125]. Loss of *Nfix* also causes apoptosis in murine hematopoietic stem cells [126]. However, its importance in hematopoietic tumours is yet to be investigated. Taken together, the NFI transcription factors are essential in regulating lineage progression, differentiation, and the survival of hematopoietic cells. The dysregulation of these proteins may contribute to hematopoietic tumour growth.

Other tumours

NFI transcription factors have also been implicated in other tumour types such as melanoma, osteosarcoma, neurofibroma, and benign tumours, although their role in these tumours is less clear. In human melanomas, genomic aberrations within the NFI genes, including single nucleotide polymorphism and translocations, have been observed [127–129] (Tables 1 and 3). Insertions within Nfia were also observed in tumours derived from an insertional mutagenesis melanoma mouse model [130] (Table 2a), suggesting that NFIA could act as a tumour suppressor in melanoma. NFIB expression, on the other hand, correlates with more aggressive melanomas and promotes melanoma cell migration and invasiveness [35], suggesting that NFIB acts as an oncogene in this case. However, this role is contradicted by the inability of NFIBoverexpressing cells to form tumours when xenografted into immune-compromised mice [35]. Functional studies using uveal melanoma cells that originate from the same cell population that gives rise to cutaneous melanoma [131] have demonstrated that overexpression of NFIB and NFIC promotes cell migration and metastasis through suppression of an integrin subunit [132]. Inducing human melanoblast differentiation during development results in the down-regulation of NFIB expression [35], and its deletion in mice enhances melanocyte stem cell self renewal [36]. These findings demonstrate that NFIB expression is important in maintaining the quiescent state of melanocyte stem cells. This may explain why overexpression of NFIB in a pre-cultured melanoma cell line is insufficient to form xenograft tumours in mice [35].

In human osteosarcomas, a missense coding SNP in NFIB and decreased NFIB expression have been associated with increased metastasis [133] (Table 1). A direct role for loss of NFIB in metastatic disease is substantiated by increased cell migration in vitro when NFIB levels are decreased [133] and the identification of disrupting insertions in Nfib in metastases collected from an insertional mutagenesis osteosarcoma mouse model [134] (Table 2a). These findings suggest that disruption of NFIB contributes to the osteosarcoma metastasis. This function is similar to its role in osteoblast development. In human osteoblast and bone formation, NFIB and NFIC are highly expressed and transcriptionally regulate cell proliferation, differentiation and survival through insulin-like growth factor binding proteins [32]. In addition, the disruption of NFIC causes defects in bone formation due to the failure of osteoblast differentiation and epithelial cell migration [33,34]. Reduced expression of NFIC is also observed in dedifferentiated osteosarcoma cells [135]. These findings suggest that disruption of the NFI transcription factors perturbs cell differentiation and migration, possibly leading to tumorigenesis and metastasis.

The NFI transcription factors have also been implicated in benign tumours, although the reasons for this remains unclear. For example, disruption of NFI promotes the progression of benign neurofibromatosis to malignant peripheral nerve sheath tumours as shown in insertional mutagenesis mouse models where insertions within *Nfia* or *Nfib* were identified [136] (Table 2a). In other benign tumours, only translocations involving *NFIB* have been reported, such as the *HMGA2-NFIB* translocations that are commonly found in lipoma [137,138], pleomorphic adenoma [139], and uterine leiomyoma [140,141] (Table 3). Interestingly, the *MYB-NFIB* fusion that is characteristic of AdCC is also found in dermal cylindroma (Table 3), suggesting that similar pathways may be maladapted in these disorders [142].

Discussion

The context-dependent roles of NFI in cancer

Advances in high-throughput sequencing technologies have resulted in the identification of aberrations affecting NFI expression or function in various cancer types. Hence, there is now a body of evidence to suggest that the NFI family of transcription factors have both oncogenic and tumour-suppressive potential, depending on the context. This holds true across different tumour types, but also applies to the role of the different NFI family members within a single tumour type. For instance, NFIB may be oncogenic in ERnegative breast cancers and SCLC, but likely functions as a tumour suppressor in AdCC and GBM. Similarly, although it has been reported that high expression of both NFIA and NFIB correlates with improved clinical outcome and lower grade astrocytomas [37,38], other studies have suggested that NFIA and NFIB can function in opposing roles. In vivo overexpression of NFIA in glioma promotes cell proliferation and tumour growth [200,201], whereas overexpression of NFIB induces differentiation, thereby halting tumour growth [38]. Finally, a single NFI transcription factor can perform opposing roles within the same tumour type, depending on the molecular context. Overexpression of NFIB inhibits cell proliferation and tumour growth by activating phospho-STAT3 signalling in STAT3-expressing GBM, but not in GBM without STAT3 expression [38]. It is likely that these differences are due to the transcriptional and post-translational regulation of the NFI genes themselves, and their subsequent recruitment of different molecular/protein co-activators or co-repressors to regulate downstream transcription. These differences accentuate the need to understand tumour context and the molecular pathways involved before assigning a function to specific NFI transcription factors in different cancer types. More importantly, careful consideration is required when targeting signalling pathways during treatment, as misapprehensions and poor treatment choice could in fact accelerate tumour progression.

Regulatory mechanisms governing NFI expression

NFI genes have been shown to be regulated in a variety of cancers through changes in gene copy number, both amplification of the gene and LOH, which alter mRNA expression, but this can also be altered via methylation and microRNA's. Amplification of the *NFIB* locus and corresponding high *NFIB* expression have been reported in SCLC [85,86], ER-negative breast carcinoma [94–98], and esophageal squamous cell carcinoma [196], suggesting that NFIB functions as an oncogene in these tumour types. In contrast, LOH or deletions causing low *NFIB* expression is common in astrocytomas [42–46], myeloproliferative neoplasms [117–119], T-

cell lymphomas [120], and hepatocellular carcinoma [166,197]. Similarly, LOH and low *NFIA* expression was found in oligodendroglioma [52–54], myeloproliferative neoplasms [114,115], and hepatocellular carcinoma [166,197]. These studies suggest potential roles for *NFIA* and *NFIB* as tumour suppressors, which are also corroborated in insertional mutagenesis mouse models (Table 2a), as well as *in vitro* and *in vivo* studies [37,38].

Promoter methylation of the different *NFI* promoters has not been well studied in the context of cancer. In a recent study of NSCLC samples with low *NFIB* expression, *NFIB* promoter hypermethylation was not observed, and only 6% of samples demonstrated *NFIB* copy number loss [90]. In these samples, *NFIB* was down-regulated as a result of tumour specific expression of miR-212 and miR-92b [90]. These findings suggest that microRNA dysregulation may be a common pathway resulting in *NFI* downregulation in cancer.

The *NFI* loci are targeted by a number of miRNAs that are dysregulated in cancer, such as miR-21, miR-223, miR-124, miR-129, and miR-191 [28,90,153,202–205]. For instance, expression of miR-124 and miR-129 in astrocytoma is inversely correlated with expression of their target *NFIB* and increased tumour grade [153,205,206]. Although *in vitro* experiments have demonstrated microRNA regulation of *NFI* in tumour cells in these cases [28,90,153,202–204], the importance of *NFI* as a target *in vivo* remains to be determined.

Structural variations alter function of NFI proteins

The expression of naturally occurring NFI isoforms due to alternative mRNA splicing, particularly at the C-terminus transactivation domain (Fig. 1), might be a key determinant of the function of NFI proteins in development and cancer. Most differences between isoforms occur in the C-terminal transactivation and repression domain, and are likely to alter protein function. For example, the NFI-X1 isoform (Fig. 1, NFIX variant iv), in which exon 9 is skipped, is not able to induce glial fibrillary acidic protein (GFAP) expression [207]. On the other hand, the full length NFI-X3 isoform (Fig. 1, NFIX variant ii) can induce the expression of GFAP, resulting in astrocytic differentiation from neural progenitors [207]. This isoform also promotes the migration of glioma cells in vitro [11]. Some isoforms completely lack the DNA binding domain or transactivation domain and are likely to result in the loss-offunction of these proteins. For example, the NFI-B3 isoform (Fig. 1, NFIB variant vii) lacks a transactivation domain and consists only of a truncated DNA binding domain. This isoform is able to bind to its motif in DNA but does not activate gene transcription [7], suggesting that it may act as a dominant negative isoform and antagonise normal NFI function. Given that little is known about the precise function or expression of the different NFI isoforms. expression of specific NFI isoforms may explain the contradictory roles observed in some cancer types, such as that of NFIB in SCLC and NSCLC. More in-depth analyses of available mRNA-sequencing data or proteomic analyses will be required to understand the function of NFI genes in different tumour contexts.

Potential role of post-translational modifications on NFI protein function

A further layer of complexity that requires consideration is how post-translational modifications of the NFI transactivation domain may affect their function (Fig. 1). For instance, phosphorylation of NFI is required to induce the expression of glial differentiation markers in glioma cells [15,16], whereas glycosylation of NFI is mandatory in activating the transcription of whey acidic protein [8], and recruiting co-activators, repressors or other nuclear regulatory targets [14] during mammary gland development. In contrast to its role in mammary gland development, glycosylation appears disruptive for NFI function in the differentiation of skin keratinocytes [13], suggesting that glycosylation of NFI could confer multiple functions. A major limitation of these studies is that they have not identified the exact amino acid residues that are modified [8,12–16]. Other post-translational modifications of NFI, including SUMOylation [12] and acetylation [208], are also observed. However, similar to NFI phosphorylation, the physiological functions of these modifications have not been determined. Hence, proteomic analyses such as mass spectrometry will be useful for identifying the presence of NFIpost-translational modifications in order to obtain a more accurate interpretation of NFI function in cancer.

Potential impact of mutations on NFI function in cancer

Mutations provide another scenario through which NFI function is altered in cancer. The most prevelant *NFI* mutation is the translocation of *NFIB* and *MYB* or *MYBL* in AdCC (Table 3). The presence of other translocation partners and nonsense mutations affecting *NFIB* in AdCC [70,75,78–82] suggest that NFIB may act as a tumour suppressor in this tumour type. Although many other translocations involving *NFI* have been reported (Table 3), their functional consequence or relevance remains to be determined.

Missense mutations in the *NFI* loci have been observed in up to 10% of melanoma and uterine carcinoma samples [209–211]. How these mutations affect NFI function remains to be determined, but no clear mutational hotspots or recurrent mutations are reported. It is likely that many of these mutations are passenger mutations due to the high mutation rate in some cancer types.

Truncating mutations of *NFI* genes are uncommon, but have been reported for tumours in which a tumour suppressor role has been proposed, including AdCC [70], medulloblastoma [212], and GBM [184]. Such mutations may function as dominant negative mutations if they result in an antagonising function similar to NFI-B3. Thus, these mutations may provide additional evidence for the proposed role of NFI in these specific tumour types.

The convergent roles of NFI in development and cancer

Despite these challenges, the role of the NFI transcription factors in regulating the balance between cellular proliferation and differentiation/quiescence during development appears conserved in the context of cancer. This is advantageous as it allows us to consider how the normal function of these genes might be disrupted in cancer, particularly in relation to tumour initiation and progression. For example, the NFI transcription factors and STAT3 bind to the GFAP promoter to drive astrocytic differentiation during development [213]. An appreciation of this relationship proved useful in our discovery that STAT3 is required for NFIB to inhibit proliferation in glioblastoma both *in vitro* and *in vivo* [38]. Similarly, the antagonistic relationship between SOX10 and NFIA in regulating glioma subtypes resembles their role in the lineage progression of glial cells during development [55].

In conclusion, the role of the NFI transcription factors in development is highly convergent with their role in cancer when their expression is disrupted. Also, there appears to be a tendency for the NFI transcription factors to be implicated in tumours that arise from cells that normally express the concordant transcription factor during development. We posit that an in-depth understanding of the correlation between NFI function in development and tumorigenesis will contribute greatly to understanding NFI function in cancer, and may ultimately be of prognostic and therapeutic value in overcoming these diseases.

Acknowledgements

KSC was supported by a University of Queensland (UQ) International Postgraduate Student Scholarship and JWCL by an Australian Government Research Training Program Scholarship and UQ Centennial Scholarship. LJR was supported by an NHMRC Principal Research Fellowship (GNT1120615). JB was supported by the Scott Canner Young Researcher Grant from Tour de Cure. This work was supported by National Health and Medical Research Council project grant (GNT1100443 to LJR) and Ride for Rhonda.

Conflict of interest

The authors declare no conflicts of interest.

Appendix A. Supplementary data

Supplementary data related to this article can be found at https://doi.org/10.1016/j.canlet.2017.09.015.

References

- D. Hanahan, R.A. Weinberg, Hallmarks of cancer: the next generation, Cell 144 (2011) 646–674.
- [2] Y. Ma, P. Zhang, F. Wang, J. Yang, Z. Yang, H. Qin, The relationship between early embryo development and tumourigenesis, J. Cell. Mol. Med. 14 (2010) 2697–2701.
- [3] R.M. Gronostajski, Roles of the NFI/CTF gene family in transcription and development, Gene 249 (2000) 31–45.
- [4] S. Mason, M. Piper, R.M. Gronostajski, LJ. Richards, Nuclear factor one transcription factors in CNS development, Mol. Neurobiol. 39 (2009) 10–23.
- [5] R.M. Gronostajski, S. Adhya, K. Nagata, R.A. Guggenheimer, J. Hurwitz, Sitespecific DNA binding of nuclear factor I: analyses of cellular binding sites, Mol. Cell. Biol. 5 (1985) 964–971.
- [6] A. Jolma, J. Yan, T. Whitington, J. Toivonen, K.R. Nitta, P. Rastas, et al., DNAbinding specificities of human transcription factors, Cell 152 (2013) 327–339.
- [7] Y. Liu, H.U. Bernard, D. Apt, NFI-B3, a novel transcriptional repressor of the nuclear factor I family, is generated by alternative RNA processing, J. Biol. Chem. 272 (1997) 10739–10745.
- [8] S.S. Mukhopadhyay, J.M. Rosen, The C-terminal domain of the nuclear factor I-B2 isoform is glycosylated and transactivates the WAP gene in the JEG-3 cells, Biochem. Biophys. Res. Commun. 358 (2007) 770–776.
 [9] J. Nilsson, K. Helou, A. Kovacs, P.O. Bendahl, G. Bjursell, M. Ferno, et al.,
- [9] J. Nilsson, K. Helou, A. Kovacs, P.O. Bendahl, G. Bjursell, M. Ferno, et al., Nuclear Janus-activated kinase 2/nuclear factor 1-C2 suppresses tumorigenesis and epithelial-to-mesenchymal transition by repressing Forkhead box F1, Cancer Res. 70 (2010) 2020–2029.
- [10] R.A. Rupp, U. Kruse, G. Multhaup, U. Gobel, K. Beyreuther, A.E. Sippel, Chicken NFI/TGGCA proteins are encoded by at least three independent genes: NFI-A, NFI-B and NFI-C with homologues in mammalian genomes, Nucleic Acids Res. 18 (1990) 2607–2616.
- [11] S.K. Singh, R. Bhardwaj, K.M. Wilczynska, C.I. Dumur, T. Kordula, A complex of nuclear factor I-X3 and STAT3 regulates astrocyte and glioma migration through the secreted glycoprotein YKL-40, J. Biol. Chem. 286 (2011) 39893–39903.
- [12] S.H. Yang, A. Galanis, J. Witty, A.D. Sharrocks, An extended consensus motif enhances the specificity of substrate modification by SUMO, EMBO J. 25 (2006) 5083-5093.
- [13] C. Duval, M. Gaudreault, F. Vigneault, L. Touzel-Deschenes, P.J. Rochette, B. Masson-Gadais, et al., Rescue of the transcription factors Sp1 and NFI in human skin keratinocytes through a feeder-layer-dependent suppression of the proteasome activity, J. Mol. Biol. 418 (2012) 281–299.
- [14] R. Kane, J. Murtagh, D. Finlay, A. Marti, R. Jaggi, D. Blatchford, et al., Transcription factor NFIC undergoes N-glycosylation during early mammary gland involution, J. Biol. Chem. 277 (2002) 25893–25903.
- [15] D.A. Bisgrove, E.A. Monckton, M. Packer, R. Godbout, Regulation of brain fatty acid-binding protein expression by differential phosphorylation of nuclear factor I in malignant glioma cell lines, J. Biol. Chem. 275 (2000) 30668–30676.
- [16] M. Brun, J.E. Coles, E.A. Monckton, D.D. Glubrecht, D. Bisgrove, R. Godbout, Nuclear factor I regulates brain fatty acid-binding protein and glial fibrillary acidic protein gene expression in malignant glioma cell lines, J. Mol. Biol. 391 (2009) 282–300.
- [17] M. Piper, R.X. Moldrich, C. Lindwall, E. Little, G. Barry, S. Mason, et al., Multiple non-cell-autonomous defects underlie neocortical callosal dysgenesis in Nfib-deficient mice, Neural Dev. 4 (2009) 43.

- [18] G. Steele-Perkins, C. Plachez, K.G. Butz, G. Yang, C.J. Bachurski, S.L. Kinsman, et al., The transcription factor gene Nfib is essential for both lung maturation and brain development, Mol. Cell. Biol. 25 (2005) 685–698.
- M. Piper, G. Barry, T.J. Harvey, R. McLeay, A.G. Smith, L. Harris, et al., NFIB-mediated repression of the epigenetic factor Ezh2 regulates cortical development, J. Neurosci. 34 (2014) 2921–2930.
 T. Shu, K.G. Butz, C. Plachez, R.M. Gronostajski, L.J. Richards, Abnormal
- [20] T. Shu, K.G. Butz, C. Plachez, R.M. Gronostajski, L.J. Richards, Abnormal development of forebrain midline glia and commissural projections in Nfia knock-out mice, J. Neurosci. 23 (2003) 203–212.
- [21] I. Gobius, L. Morcom, R. Suarez, J. Bunt, P. Bukshpun, W. Reardon, et al., Astroglial-mediated remodeling of the interhemispheric midline is required for the formation of the corpus callosum, Cell Rep. 17 (2016) 735–747.
- [22] L. das Neves, C.S. Duchala, F. Tolentino-Silva, M.A. Haxhiu, C. Colmenares, W.B. Macklin, et al., Disruption of the murine nuclear factor I-A gene (Nfia) results in perinatal lethality, hydrocephalus, and agenesis of the corpus callosum, Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 11946–11951.
- [23] M. Piper, G. Barry, J. Hawkins, S. Mason, C. Lindwall, E. Little, et al., NFIA controls telencephalic progenitor cell differentiation through repression of the Notch effector Hes1, J. Neurosci. 30 (2010) 9127–9139.
 [24] J. Murtagh, F. Martin, R.M. Gronostajski, The Nuclear Factor I (NFI) gene
- [24] J. Murtagh, F. Martin, R.M. Gronostajski, The Nuclear Factor I (NFI) gene family in mammary gland development and function, J. Mammary Gland. Biol. Neoplasia 8 (2003) 241–254.
- [25] A. Grunder, T.T. Ebel, M. Mallo, G. Schwarzkopf, T. Shimizu, A.E. Sippel, et al., Nuclear factor I-B (Nfib) deficient mice have severe lung hypoplasia, Mech. Dev. 112 (2002) 69–77.
- [26] L.M. Starnes, A. Sorrentino, M. Ferracin, M. Negrini, E. Pelosi, C. Nervi, et al., A transcriptome-wide approach reveals the key contribution of NFI-A in promoting erythroid differentiation of human CD34(+) progenitors and CML cells, Leukemia 24 (2010) 1220–1223.
- [27] L.M. Starnes, A. Sorrentino, E. Pelosi, M. Ballarino, O. Morsilli, M. Biffoni, et al., NFI-A directs the fate of hematopoietic progenitors to the erythroid or granulocytic lineage and controls beta-globin and G-CSF receptor expression, Blood 114 (2009) 1753–1763.
- [28] F. Fazi, A. Rosa, A. Fatica, V. Gelmetti, M.L. De Marchis, C. Nervi, et al., A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPalpha regulates human granulopoiesis, Cell 123 (2005) 819–831.
- [29] S. Kulkarni, R.M. Gronostajski, Altered expression of the developmentally regulated NFI gene family during phorbol ester-induced differentiation of human leukemic cells, Cell Growth Differ. 7 (1996) 501–510.
- [30] C. McClure, L. Brudecki, D.A. Ferguson, Z.Q. Yao, J.P. Moorman, C.E. McCall, et al., MicroRNA 21 (miR-21) and miR-181b couple with NFI-A to generate myeloid-derived suppressor cells and promote immunosuppression in late sepsis, Infect. Immun. 82 (2014) 3816–3825.
- [31] A. Rosa, M. Ballarino, A. Sorrentino, O. Sthandier, F.G. De Angelis, M. Marchioni, et al., The interplay between the master transcription factor PU.1 and miR-424 regulates human monocyte/macrophage differentiation, Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 19849–19854.
- [32] L.A. Perez-Casellas, X. Wang, K.D. Howard, M.W. Rehage, D.D. Strong, T.A. Linkhart, Nuclear factor I transcription factors regulate IGF binding protein 5 gene transcription in human osteoblasts, Biochim. Biophys. Acta 1789 (2009) 78–87.
- [33] G. Steele-Perkins, K.G. Butz, G.E. Lyons, M. Zeichner-David, H.J. Kim, M.I. Cho, et al., Essential role for NFI-C/CTF transcription-replication factor in tooth root development, Mol. Cell. Biol. 23 (2003) 1075–1084.
- [34] D.S. Lee, H.W. Choung, H.J. Kim, R.M. Gronostajski, Y.I. Yang, H.M. Ryoo, et al., NFI-C regulates osteoblast differentiation via control of osterix expression, Stem Cells 32 (2014) 2467–2479.
- [35] M.E. Fane, Y. Chhabra, D.E. Hollingsworth, J.L. Simmons, L. Spoerri, T.G. Oh, et al., NFIB mediates BRN2 driven melanoma cell migration and invasion through regulation of EZH2 and MITF, EBioMedicine 16 (2017) 63–75.
- [36] C.Y. Chang, H.A. Pasolli, E.G. Giannopoulou, G. Guasch, R.M. Gronostajski, O. Elemento, et al., NFIB is a governor of epithelial-melanocyte stem cell behaviour in a shared niche, Nature 495 (2013) 98–102.
- [37] H.R. Song, I. Gonzalez-Gomez, G.S. Suh, D.L. Commins, R. Sposto, F.H. Gilles, et al., Nuclear factor IA is expressed in astrocytomas and is associated with improved survival, Neuro Oncol. 12 (2010) 122–132.
- [38] B.W. Stringer, J. Bunt, B.W. Day, G. Barry, P.R. Jamieson, K.S. Ensbey, et al., Nuclear factor one B (NFIB) encodes a subtype-specific tumour suppressor in glioblastoma, Oncotarget 7 (20) (2016 May 17) 29306–29320.
- [39] I. Vyazunova, V.I. Maklakova, S. Berman, I. De, M.D. Steffen, W. Hong, et al., Sleeping Beauty mouse models identify candidate genes involved in gliomagenesis, PLoS One 9 (2014), e113489.
- [40] A.M. Bender, L.S. Collier, F.J. Rodriguez, C. Tieu, J.D. Larson, C. Halder, et al., Sleeping beauty-mediated somatic mutagenesis implicates CSF1 in the formation of high-grade astrocytomas, Cancer Res. 70 (2010) 3557–3565.
- [41] F.K. Johansson, J. Brodd, C. Eklof, M. Ferletta, G. Hesselager, C.F. Tiger, et al., Identification of candidate cancer-causing genes in mouse brain tumors by retroviral tagging, Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 11334–11337.
- [42] D.M. Roy, L.A. Walsh, A. Desrichard, J.T. Huse, W. Wu, J. Gao, et al., Integrated genomics for pinpointing survival loci within arm-level somatic copy number alterations, Cancer Cell 29 (2016) 737–750.
- [43] E.C. Burton, K.R. Lamborn, B.G. Feuerstein, M. Prados, J. Scott, P. Forsyth, et al., Genetic aberrations defined by comparative genomic hybridization distinguish long-term from typical survivors of glioblastoma, Cancer Res. 62 (2002) 6205–6210.

- [44] A. Rasheed, J.E. Herndon, T.T. Stenzel, J.G. Raetz, J. Kendelhardt, H.S. Friedman, et al., Molecular markers of prognosis in astrocytic tumors, Cancer 94 (2002) 2688–2697.
- [45] E.E. Schmidt, K. Ichimura, G. Reifenberger, V.P. Collins, CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas, Cancer Res. 54 (1994) 6321–6324.
- [46] D.G. Walker, W. Duan, E.A. Popovic, A.H. Kaye, F.H. Tomlinson, M. Lavin, Homozygous deletions of the multiple tumor suppressor gene 1 in the progression of human astrocytomas, Cancer Res. 55 (1995) 20–23.
- [47] C.E. Campbell, M. Piper, C. Plachez, Y.T. Yeh, J.S. Baizer, J.M. Osinski, et al., The transcription factor Nfix is essential for normal brain development,, BMC Dev. Biol. 8 (2008) 52.
- [48] A.Z. Chaudhry, G.E. Lyons, R.M. Gronostajski, Expression patterns of the four nuclear factor I genes during mouse embryogenesis indicate a potential role in development, Dev. Dyn. 208 (1997) 313–325.
- [49] C. Plachez, C. Lindwall, N. Sunn, M. Piper, R.X. Moldrich, C.E. Campbell, et al., Nuclear factor I gene expression in the developing forebrain, J. Comp. Neurol. 508 (2008) 385-401.
- [50] K.S. Chen, L. Harris, J.W. Lim, T.J. Harvey, M. Piper, R.M. Gronostajski, et al., Differential neuronal and glial expression of Nuclear factor I proteins in the cerebral cortex of adult mice, J. Comp. Neurol. 525 (11) (2017 Aug 1) 2465–2483.
- [51] Y. Sun, W. Zhang, D. Chen, Y. Lv, J. Zheng, H. Lilljebjorn, et al., A glioma classification scheme based on coexpression modules of EGFR and PDGFRA, Proc. Natl. Acad. Sci. U. S. A. 111 (2014) 3538–3543.
- [52] C. Dehais, F. Laigle-Donadey, Y. Marie, M. Kujas, J. Lejeune, A. Benouaich-Amiel, et al., Prognostic stratification of patients with anaplastic gliomas according to genetic profile, Cancer 107 (2006) 1891–1897.
- [53] C. Houillier, K. Mokhtari, C. Carpentier, E. Criniere, Y. Marie, A. Rousseau, et al., Chromosome 9p and 10q losses predict unfavorable outcome in lowgrade gliomas, Neuro Oncol. 12 (2010) 2–6.
- [54] A. Idbaih, M. Kouwenhoven, J. Jeuken, C. Carpentier, T. Gorlia, J.M. Kros, et al., Chromosome 1p loss evaluation in anaplastic oligodendrogliomas, Neuropathology 28 (2008) 440–443.
- [55] S.M. Glasgow, W. Zhu, C.C. Stolt, T.W. Huang, F. Chen, J.J. LoTurco, et al., Mutual antagonism between Sox10 and NFIA regulates diversification of glial lineages and glioma subtypes, Nat. Neurosci. 17 (2014) 1322–1329.
 [56] M. Caiazzo, S. Giannelli, P. Valente, G. Lignani, A. Carissimo, A. Sessa, et al.,
- [56] M. Caiazzo, S. Giannelli, P. Valente, G. Lignani, A. Carissimo, A. Sessa, et al., Direct conversion of fibroblasts into functional astrocytes by defined transcription factors, Stem Cell Rep. 4 (2015) 25–36.
- [57] Y.W. Wong, C. Schulze, T. Streichert, R.M. Gronostajski, M. Schachner, T. Tilling, Gene expression analysis of nuclear factor I-A deficient mice indicates delayed brain maturation, Genome Biol. 8 (2007), R72.
- [58] L.A. Genovesi, C.G. Ng, M.J. Davis, M. Remke, M.D. Taylor, D.J. Adams, et al., Sleeping Beauty mutagenesis in a mouse medulloblastoma model defines networks that discriminate between human molecular subgroups, Proc. Natl. Acad. Sci. U. S. A. 110 (2013) E4325–E4334.
- [59] M. Lastowska, H. Al-Afghani, H.H. Al-Balool, H. Sheth, E. Mercer, J.M. Coxhead, et al., Identification of a neuronal transcription factor network involved in medulloblastoma development, Acta Neuropathol. Commun. 1 (2013) 35.
- [60] X. Wu, P.A. Northcott, A. Dubuc, A.J. Dupuy, D.J. Shih, H. Witt, et al., Clonal selection drives genetic divergence of metastatic medulloblastoma, Nature 482 (2012) 529–533.
- [61] N. McCarthy, Medulloblastoma: origins, Nat. Rev. Cancer 11 (2011) 80.
- [62] W. Wang, D. Mullikin-Kilpatrick, J.E. Crandall, R.M. Gronostajski, E.D. Litwack, D.L. Kilpatrick, Nuclear factor I coordinates multiple phases of cerebellar granule cell development via regulation of cell adhesion molecules, J. Neurosci. 27 (2007) 6115–6127.
- [63] M. Piper, L. Harris, G. Barry, Y.H. Heng, C. Plachez, R.M. Gronostajski, et al., Nuclear factor one X regulates the development of multiple cellular populations in the postnatal cerebellum, J. Comp. Neurol. 519 (2011) 3532–3548.
- [64] W. Wang, J.E. Crandall, E.D. Litwack, R.M. Gronostajski, D.L. Kilpatrick, Targets of the nuclear factor I regulon involved in early and late development of postmitotic cerebellar granule neurons, J. Neurosci. Res. 88 (2010) 258–265.
- [65] B. Ding, W. Wang, T. Selvakumar, H.S. Xi, H. Zhu, C.W. Chow, et al., Temporal regulation of nuclear factor one occupancy by calcineurin/NFAT governs a voltage-sensitive developmental switch in late maturing neurons, J. Neurosci. 33 (2013) 2860–2872.
- [66] W. Wang, R.E. Stock, R.M. Gronostajski, Y.W. Wong, M. Schachner, D.L. Kilpatrick, A role for nuclear factor I in the intrinsic control of cerebellar granule neuron gene expression, J. Biol. Chem. 279 (2004) 53491–53497.
- [67] K.J. Brayer, C.A. Frerich, H. Kang, S.A. Ness, Recurrent fusions in MYB and MYBL1 define a common, transcription factor-driven oncogenic pathway in salivary gland adenoid cystic carcinoma, Cancer Discov. 6 (2016) 176–187.
- [68] L.B. Brill 2nd, W.A. Kanner, A. Fehr, Y. Andren, C.A. Moskaluk, T. Loning, et al., Analysis of MYB expression and MYB-NFIB gene fusions in adenoid cystic carcinoma and other salivary neoplasms, Mod. Pathol. 24 (2011) 1169–1176.
- [69] A.F. Costa, A. Altemani, C. Garcia-Inclan, F. Fresno, C. Suarez, J.L. Llorente, et al., Analysis of MYB oncogene in transformed adenoid cystic carcinomas reveals distinct pathways of tumor progression, Lab. Invest. 94 (2014) 692–702.
- [70] A.S. Ho, K. Kannan, D.M. Roy, L.G. Morris, I. Ganly, N. Katabi, et al., The mutational landscape of adenoid cystic carcinoma, Nat. Genet. 45 (2013) 791–798.

- [71] Y. Mitani, P.H. Rao, P.A. Futreal, D.B. Roberts, P.J. Stephens, Y.J. Zhao, et al., Novel chromosomal rearrangements and break points at the t(6;9) in salivary adenoid cystic carcinoma: association with MYB-NFIB chimeric fusion, MYB expression, and clinical outcome, Clin. Cancer Res. 17 (2011) 7003–7014.
- [72] C.A. Moskaluk, A.S. Baras, S.A. Mancuso, H. Fan, R.J. Davidson, D.C. Dirks, et al., Development and characterization of xenograft model systems for adenoid cystic carcinoma, Lab. Invest. 91 (2011) 1480–1490.
- [73] M. Persson, Y. Andren, J. Mark, H.M. Horlings, F. Persson, G. Stenman, Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck, Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 18740–18744.
- [74] R.B. West, C. Kong, N. Clarke, T. Gilks, J.S. Lipsick, H. Cao, et al., MYB expression and translocation in adenoid cystic carcinomas and other salivary gland tumors with clinicopathologic correlation, Am. J. Surg. Pathol. 35 (2011) 92–99.
- [75] K. Yoshihara, Q. Wang, W. Torres-Garcia, S. Zheng, R. Vegesna, H. Kim, et al., The landscape and therapeutic relevance of cancer-associated transcript fusions, Oncogene 34 (2015) 4845–4854.
- [76] K. Fujii, T. Murase, S. Beppu, K. Saida, H. Takino, A. Masaki, et al., MYB, MYBL1, MYBL2, and NFIB gene alterations and MYC overexpression in salivary gland adenoid cystic carcinoma, Histopathology (2017 Jun 8), https:// doi.org/10.1111/his.13281 (Epub ahead of print).
- [77] N. Fusco, E. Guerini-Rocco, A.M. Schultheis, S.S. Badve, J.S. Reis-Filho, B. Weigelt, The birth of an adenoid cystic carcinoma, Int. J. Surg. Pathol. 23 (2015) 26–27.
- [78] Y. Drier, M.J. Cotton, K.E. Williamson, S.M. Gillespie, R.J. Ryan, M.J. Kluk, et al., An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma, Nat. Genet. 48 (2016) 265–272.
- [79] E.M. Rettig, C.C. Talbot Jr., M. Sausen, S. Jones, J.A. Bishop, L.D. Wood, et al., Whole-Genome sequencing of salivary gland adenoid cystic carcinoma, Cancer Prev. Res. (Phila.) 9 (2016) 265–274.
- [80] Y. Mitani, B. Liu, P.H. Rao, V.J. Borra, M. Zafereo, R.S. Weber, et al., Novel MYBL1 gene rearrangements with recurrent MYBL1-NFIB fusions in salivary adenoid cystic carcinomas lacking t(6;9) translocations, Clin. Cancer Res. 22 (2016) 725–733.
- [81] D. Xing, S. Bakhsh, N. Melnyk, C. Isacson, J. Ho, D.G. Huntsman, et al., Frequent NFIB-associated gene rearrangement in adenoid cystic carcinoma of the vulva, Int. J. Gynecol. Pathol. 36 (3) (2017 May) 289–293.
- [82] Y. Mitani, J. Li, P.H. Rao, Y.J. Zhao, D. Bell, S.M. Lippman, et al., Comprehensive analysis of the MYPA-NFIB gene fusion in salivary adenoid cystic carcinoma: incidence, variability, and clinicopathologic significance, Clin. Cancer Res. 16 (2010) 4722–4731.
- [83] R.E. Mellas, H. Kim, J. Osinski, S. Sadibasic, R.M. Gronostajski, M. Cho, et al., NFIB regulates embryonic development of submandibular glands, J. Dent. Res. 94 (2015) 312–319.
- [84] R.L. Dodd, N.J. Slevin, Salivary gland adenoid cystic carcinoma: a review of chemotherapy and molecular therapies, Oral Oncol. 42 (2006) 759–769.
- [85] A.L. Dooley, M.M. Winslow, D.Y. Chiang, S. Banerji, N. Stransky, T.L. Dayton, et al., Nuclear factor I/B is an oncogene in small cell lung cancer, Genes Dev. 25 (2011) 1470–1475.
- [86] R. Iwakawa, M. Takenaka, T. Kohno, Y. Shimada, Y. Totoki, T. Shibata, et al., Genome-wide identification of genes with amplification and/or fusion in small cell lung cancer, Genes Chromosom. Cancer 52 (2013) 802–816.
- [87] S.K. Denny, D. Yang, C.H. Chuang, J.J. Brady, J.S. Lim, B.M. Gruner, et al., Nfib promotes metastasis through a widespread increase in chromatin accessibility, Cell 166 (2016) 328–342.
- [88] E.A. Semenova, M.C. Kwon, K. Monkhorst, J.Y. Song, R. Bhaskaran, O. Krijgsman, et al., Transcription factor NFIB is a driver of small cell lung cancer progression in mice and marks metastatic disease in patients, Cell Rep. 16 (3) (2016 Jul 19) 631–643.
- [89] N. Wu, D. Jia, A.H. Ibrahim, C.J. Bachurski, R.M. Gronostajski, D. MacPherson, NFIB overexpression cooperates with Rb/p53 deletion to promote small cell lung cancer, Oncotarget 7 (36) (2016 Sep 6) 57514–57524.
- [90] D.D. Becker-Santos, K.L. Thu, J.C. English, L.A. Pikor, V.D. Martinez, M. Zhang, et al., Developmental transcription factor NFIB is a putative target of oncofetal miRNAs and is associated with tumour aggressiveness in lung adenocarcinoma, J. Pathol. 240 (2) (2016 Oct) 161–172.
- [91] L. Du, S. Yamamoto, B.L. Burnette, D. Huang, K. Gao, N. Jamshidi, et al., Transcriptome profiling reveals novel gene expression signatures and regulating transcription factors of TGFbeta-induced epithelial-to-mesenchymal transition, Cancer Med. 5 (8) (2016 Aug) 1962–1972.
- [92] C.F. Kim, E.L. Jackson, A.E. Woolfenden, S. Lawrence, I. Babar, S. Vogel, et al., Identification of bronchioalveolar stem cells in normal lung and lung cancer, Cell 121 (2005) 823–835.
- [93] R. Meuwissen, S.C. Linn, R.I. Linnoila, J. Zevenhoven, W.J. Mooi, A. Berns, Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model, Cancer Cell 4 (2003) 181–189.
- [94] B. Kreike, M. van Kouwenhove, H. Horlings, B. Weigelt, H. Peterse, H. Bartelink, et al., Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas, Breast Cancer Res. 9 (2007), R65.
- [95] H.G. Moon, K.T. Hwang, J.A. Kim, H.S. Kim, M.J. Lee, E.M. Jung, et al., NFIB is a potential target for estrogen receptor-negative breast cancers, Mol. Oncol. 5 (2011) 538–544.

- [96] D.D. Smith, P. Saetrom, O. Snove Jr., C. Lundberg, G.E. Rivas, C. Glackin, et al., Meta-analysis of breast cancer microarray studies in conjunction with conserved cis-elements suggest patterns for coordinate regulation, BMC Bioinforma. 9 (2008) 63.
- [97] W. Han, E.M. Jung, J. Cho, J.W. Lee, K.T. Hwang, S.J. Yang, et al., DNA copy number alterations and expression of relevant genes in triple-negative breast cancer, Genes Chromosom. Cancer 47 (2008) 490–499.
- [98] M. Ly, A. Valent, G. Diallo, F. Penault-Lorca, K. Dumke, V. Marty, et al., Gene copy number variations in breast cancer of Sub-Saharan African women, Breast 22 (2013) 295–300.
- [99] C. Hatzis, L. Pusztai, V. Valero, D.J. Booser, L. Esserman, A. Lluch, et al., A genomic predictor of response and survival following taxaneanthracycline chemotherapy for invasive breast cancer, JAMA 305 (2011) 1873–1881.
- [100] J. Eeckhoute, J.S. Carroll, T.R. Geistlinger, M.I. Torres-Arzayus, M. Brown, A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer, Genes Dev. 20 (2006) 2513–2526.
- [101] R. Kane, D. Finlay, T. Lamb, F. Martin, Transcription factor NF 1 expression in involuting mammary gland, Adv. Exp. Med. Biol. 480 (2000) 117–122.
- [102] H. Lubon, L. Hennighausen, Conserved region of the rat alpha-lactalbumin promoter is a target site for protein binding in vitro, Biochem. J. 256 (1988) 391–396.
- [103] S. Mink, E. Hartig, P. Jennewein, W. Doppler, A.C. Cato, A mammary cell-specific enhancer in mouse mammary tumor virus DNA is composed of multiple regulatory elements including binding sites for CTF/NFI and a novel transcription factor, mammary cell-activating factor, Mol. Cell. Biol. 12 (1992) 4906–4918.
- [104] S.S. Mukhopadhyay, S.L. Wyszomierski, R.M. Gronostajski, J.M. Rosen, Differential interactions of specific nuclear factor I isoforms with the glucocorticoid receptor and STAT5 in the cooperative regulation of WAP gene transcription, Mol. Cell. Biol. 21 (2001) 6859–6869.
- [105] C.J. Watson, K.E. Gordon, M. Robertson, A.J. Clark, Interaction of DNAbinding proteins with a milk protein gene promoter in vitro: identification of a mammary gland-specific factor, Nucleic Acids Res. 19 (1991) 6603–6610.
- [106] S. Li, J.M. Rosen, Distal regulatory elements required for rat whey acidic protein gene expression in transgenic mice, J. Biol. Chem. 269 (1994) 14235–14243.
- [107] S. Li, J.M. Rosen, Nuclear factor I and mammary gland factor (STAT5) play a critical role in regulating rat whey acidic protein gene expression in transgenic mice, Mol. Cell. Biol. 15 (1995) 2063–2070.
- [108] B. Rajput, N.L. Shaper, J.H. Shaper, Transcriptional regulation of murine beta1,4-galactosyltransferase in somatic cells. Analysis of a gene that serves both a housekeeping and a mammary gland-specific function, J. Biol. Chem. 271 (1996) 5131–5142.
- [109] M. Kannius-Janson, E.M. Johansson, G. Bjursell, J. Nilsson, Nuclear factor 1-C2 contributes to the tissue-specific activation of a milk protein gene in the differentiating mammary gland, J. Biol. Chem. 277 (2002) 17589–17596.
- [110] M. Kannius-Janson, U. Lidberg, K. Hulten, A. Gritli-Linde, G. Bjursell, J. Nilsson, Studies of the regulation of the mouse carboxyl ester lipase gene in mammary gland, Biochem. J. 336 (Pt 3) (1998) 577-585.
- [111] E.E. Furlong, N.K. Keon, F.D. Thornton, T. Rein, F. Martin, Expression of a 74kDa nuclear factor 1 (NF1) protein is induced in mouse mammary gland involution. Involution-enhanced occupation of a twin NF1 binding element in the testosterone-repressed prostate message-2/clusterin promoter, J. Biol. Chem. 271 (1996) 29688–29697.
- [112] G.W. Robinson, K. Kang, K.H. Yoo, Y. Tang, B.M. Zhu, D. Yamaji, et al., Coregulation of genetic programs by the transcription factors NFIB and STAT5, Mol. Endocrinol. 28 (2014) 758–767.
- [113] E.M. Johansson, M. Kannius-Janson, A. Gritli-Linde, G. Bjursell, J. Nilsson, Nuclear factor 1-C2 is regulated by prolactin and shows a distinct expression pattern in the mouse mammary epithelial cells during development, Mol. Endocrinol. 19 (2005) 992–1003.
- [114] F. Bernard, V. Gelsi-Boyer, A. Murati, S. Giraudier, V. Trouplin, J. Adelaide, et al., Alterations of NFIA in chronic malignant myeloid diseases, Leukemia 23 (2009) 583-585.
- [115] I. Ivanov Ofverholm, A.N. Tran, L. Olsson, V. Zachariadis, M. Heyman, E. Rudd, et al., Detailed gene dose analysis reveals recurrent focal gene deletions in pediatric B-cell precursor acute lymphoblastic leukemia, Leuk. Lymphoma (2016) 1–10.
- [116] F. Micci, J. Thorsen, I. Panagopoulos, K.B. Nyquist, B. Zeller, A. Tierens, et al., High-throughput sequencing identifies an NFIA/CBFA2T3 fusion gene in acute erythroid leukemia with t(1;16)(p31;q24), Leukemia 27 (2013) 980–982.
- [117] R. Kralovics, A.S. Buser, S.S. Teo, J. Coers, A. Tichelli, A.P. van der Maas, et al., Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders, Blood 102 (2003) 1869–1871.
- [118] R. Kralovics, Y. Guan, J.T. Prchal, Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera, Exp. Hematol. 30 (2002) 229–236.
- [119] K.L. Rice, X. Lin, K. Wolniak, B.L. Ebert, W. Berkofsky-Fessler, M. Buzzai, et al., Analysis of genomic aberrations and gene expression profiling identifies novel lesions and pathways in myeloproliferative neoplasms, Blood Cancer J. 1 (2011), e40.

- [120] X. Mao, T. Chaplin, B.D. Young, Integrated genomic analysis of sezary syndrome, Genet. Res. Int. 2011 (2011), 980150.
- [121] K.E. Berquam-Vrieze, K. Nannapaneni, B.T. Brett, L. Holmfeldt, J. Ma, O. Zagorodna, et al., Cell of origin strongly influences genetic selection in a mouse model of T-ALL, Blood 118 (2011) 4646–4656.
- [122] O. Bluteau, T. Langlois, P. Rivera-Munoz, F. Favale, P. Rameau, G. Meurice, et al., Developmental changes in human megakaryopoiesis, J. Thromb. Haemost. 11 (2013) 1730–1741.
- [123] B. Psaila, N. Barkas, D. Iskander, A. Roy, S. Anderson, N. Ashley, et al., Singlecell profiling of human megakaryocyte-erythroid progenitors identifies distinct megakaryocyte and erythroid differentiation pathways, Genome Biol. 17 (2016) 83.
- [124] L. Chen, M. Kostadima, J.H. Martens, G. Canu, S.P. Garcia, E. Turro, et al., Transcriptional diversity during lineage commitment of human blood progenitors, Science 345 (2014), 1251033.
- [125] C. O'Connor, J. Campos, J.M. Osinski, R.M. Gronostajski, A.M. Michie, K. Keeshan, Nfix expression critically modulates early B lymphopoiesis and myelopoiesis, PLoS One 10 (2015), e0120102.
- [126] P. Holmfeldt, J. Pardieck, A.C. Saulsberry, S.K. Nandakumar, D. Finkelstein, J.T. Gray, et al., Nfix is a novel regulator of murine hematopoietic stem and progenitor cell survival, Blood 122 (2013) 2987–2996.
- [127] M.F. Berger, E. Hodis, T.P. Heffernan, Y.L. Deribe, M.S. Lawrence, A. Protopopov, et al., Melanoma genome sequencing reveals frequent PREX2 mutations, Nature 485 (2012) 502–506.
- [128] M. Stark, N. Hayward, Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays, Cancer Res. 67 (2007) 2632–2642.
- [129] H.S. Kim, M. Jung, H.N. Kang, H. Kim, C.W. Park, S.M. Kim, et al., Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition, Oncogene 36 (23) (2017 Jun 8) 3334–3345.
- [130] D. Perna, F.A. Karreth, A.G. Rust, P.A. Perez-Mancera, M. Rashid, F. Iorio, et al., BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model, Proc. Natl. Acad. Sci. U. S. A. 112 (2015) E536–E545.
- [131] C. Belmar-Lopez, P. Mancheno-Corvo, M.A. Saornil, P. Baril, G. Vassaux, M. Quintanilla, et al., Uveal vs. cutaneous melanoma. Origins and causes of the differences, Clin. Transl. Oncol. 10 (2008) 137–142.
- [132] S. Landreville, F. Vigneault, M.A. Bergeron, S. Leclerc, M. Gaudreault, M. Morcos, et al., Suppression of alpha5 gene expression is closely related to the tumorigenic properties of uveal melanoma cell lines, Pigment. Cell Melanoma Res. 24 (2011) 643–655.
- [133] L. Mirabello, R. Koster, B.S. Moriarity, L.G. Spector, P.S. Meltzer, J. Gary, et al., A genome-wide scan identifies variants in NFIB associated with metastasis in patients with osteosarcoma, Cancer Discov. 5 (9) (2015 Sep) 920–931.
- [134] B.S. Moriarity, G.M. Otto, E.P. Rahrmann, S.K. Rathe, N.K. Wolf, M.T. Weg, et al., A Sleeping Beauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis, Nat. Genet. 47 (2015) 615–624.
- [135] H. Zhang, Q. Mai, J. Chen, MicroRNA-210 is increased and it is required for dedifferentiation of osteosarcoma cell line, Cell Biol. Int. 41 (2017) 267–275.
- [136] E.P. Rahrmann, A.L. Watson, V.W. Keng, K. Choi, B.S. Moriarity, D.A. Beckmann, et al., Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis, Nat. Genet. 45 (2013) 756–766.
- [137] A. Italiano, N. Ebran, R. Attias, A. Chevallier, I. Monticelli, C. Mainguene, et al., NFIB rearrangement in superficial, retroperitoneal, and colonic lipomas with aberrations involving chromosome band 9p22, Genes Chromosom. Cancer 47 (2008) 971–977.
- [138] M. Nilsson, I. Panagopoulos, F. Mertens, N. Mandahl, Fusion of the HMGA2 and NFIB genes in lipoma, Virchows Arch. 447 (2005) 855–858.
- [139] J.M. Geurts, E.F. Schoenmakers, E. Roijer, A.K. Astrom, G. Stenman, W.J. van de Ven, Identification of NFIB as recurrent translocation partner gene of HMGIC in pleomorphic adenomas, Oncogene 16 (1998) 865–872.
- [140] S. Kataoka, H. Yamada, N. Hoshi, M. Kudo, H. Hareyama, N. Sakuragi, et al., Cytogenetic analysis of uterine leiomyoma: the size, histopathology and GnRHa-response in relation to chromosome karyotype, Eur. J. Obstet. Gynecol. Reprod. Biol. 110 (2003) 58–62.
- [141] M. Kiechle-Schwarz, C. Sreekantaiah, C.S. Berger, S. Pedron, M.T. Medchill, U. Surti, et al., Nonrandom cytogenetic changes in leiomyomas of the female genitourinary tract. A report of 35 cases, Cancer Genet. Cytogenet. 53 (1991) 125–136.
- [142] A. Fehr, A. Kovacs, T. Loning, H. Frierson Jr., J. van den Oord, G. Stenman, The MYB-NFIB gene fusion-a novel genetic link between adenoid cystic carcinoma and dermal cylindroma, J. Pathol. 224 (2011) 322–327.
- [143] X. Sharron Lin, L. Hu, K. Sandy, M. Correll, J. Quackenbush, C.L. Wu, et al., Differentiating progressive from nonprogressive T1 bladder cancer by gene expression profiling: applying RNA-sequencing analysis on archived specimens, Urol. Oncol. 32 (2014) 327–336.
- [144] E. Kashiwagi, H. Izumi, Y. Yasuniwa, R. Baba, Y. Doi, A. Kidani, et al., Enhanced expression of nuclear factor I/B in oxaliplatin-resistant human cancer cell lines, Cancer Sci. 102 (2011) 382–386.
- [145] D.S. Oh, M.C. Cheang, C. Fan, C.M. Perou, Radiation-induced gene signature predicts pathologic complete response to neoadjuvant chemotherapy in breast cancer patients, Radiat. Res. 181 (2014) 193–207.

- [146] J. Hu, G. Cai, Y. Xu, S. Cai, The plasma microRNA miR-1914* and -1915 suppresses chemoresistant in colorectal cancer patients by down-regulating NFIX, Curr. Mol. Med. 16 (2016) 70–82.
- [147] T. Spence, P. Sin-Chan, D. Picard, M. Barszczyk, K. Hoss, M. Lu, et al., CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entity, Acta Neuropathol. 128 (2014) 291–303.
- [148] Y. Liu, Y. Sun, R. Broaddus, J. Liu, A.K. Sood, I. Shmulevich, et al., Integrated analysis of gene expression and tumor nuclear image profiles associated with chemotherapy response in serous ovarian carcinoma, PLoS One 7 (2012), e36383.
- [149] D. Spentzos, D.A. Levine, S. Kolia, H. Otu, J. Boyd, T.A. Libermann, et al., Unique gene expression profile based on pathologic response in epithelial ovarian cancer, J. Clin. Oncol. 23 (2005) 7911–7918.
- [150] N. Mosakhani, L. Pazzaglia, M.S. Benassi, I. Borze, I. Quattrini, P. Picci, et al., MicroRNA expression profiles in metastatic and non-metastatic giant cell tumor of bone, Histol. Histopathol. 28 (2013) 671–678.
- [151] I. Quattrini, S. Pollino, L. Pazzaglia, A. Conti, C. Novello, C. Ferrari, et al., Prognostic role of nuclear factor/IB and bone remodeling proteins in metastatic giant cell tumor of bone: a retrospective study, J. Orthop. Res. 33 (2015) 1205–1211.
- [152] A.P. Patel, I. Tirosh, J.J. Trombetta, A.K. Shalek, S.M. Gillespie, H. Wakimoto, et al., Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma, Science 344 (2014) 1396–1401.
- [153] C.Y. Ho, E. Bar, C. Giannini, L. Marchionni, M.A. Karajannis, D. Zagzag, et al., MicroRNA profiling in pediatric pilocytic astrocytoma reveals biologically relevant targets, including PBX3, NFIB, and METAP2, Neuro Oncol. 15 (2013) 69–82.
- [154] Y. Hoshida, S.M. Nijman, M. Kobayashi, J.A. Chan, J.P. Brunet, D.Y. Chiang, et al., Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma, Cancer Res. 69 (2009) 7385–7392.
- [155] A. Kauffmann, F. Rosselli, V. Lazar, V. Winnepenninckx, A. Mansuet-Lupo, P. Dessen, et al., High expression of DNA repair pathways is associated with metastasis in melanoma patients, Oncogene 27 (2008) 565–573.
- [156] J. Jaeger, D. Koczan, H.J. Thiesen, S.M. Ibrahim, G. Gross, R. Spang, et al., Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues, Clin. Cancer Res. 13 (2007) 806–815.
- [157] H.M. Walline, C.M. Komarck, J.B. McHugh, E.L. Bellile, J.C. Brenner, M.E. Prince, et al., Genomic integration of high-risk HPV alters gene expression in oropharyngeal squamous cell carcinoma, Mol. Cancer Res. 14(10)(2016 Oct) 941–952.
- [158] M.D. Onken, J.P. Ehlers, L.A. Worley, J. Makita, Y. Yokota, J.W. Harbour, Functional gene expression analysis uncovers phenotypic switch in aggressive uveal melanomas, Cancer Res. 66 (2006) 4602–4609.
- [159] R. Rangel, S.C. Lee, K. Hon-Kim Ban, L. Guzman-Rojas, M.B. Mann, J.Y. Newberg, et al., Transposon mutagenesis identifies genes that cooperate with mutant Pten in breast cancer progression, Proc. Natl. Acad. Sci. U. S. A. 113 (2016) E7749–E7758.
- [160] C. Suarez-Cabrera, R.M. Quintana, A. Bravo, M.L. Casanova, A. Page, J.P. Alameda, et al., A transposon-based analysis reveals RASA1 is involved in triple-negative breast cancer, Cancer Res. 77 (2017) 1357–1368.
- [161] S.M. Kas, J.R. de Ruiter, K. Schipper, S. Annunziato, E. Schut, S. Klarenbeek, et al., Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma, Nat. Genet. 49 (2017) 1219–1230.
- [162] H.N. March, A.G. Rust, N.A. Wright, J. ten Hoeve, J. de Ridder, M. Eldridge, et al., Insertional mutagenesis identifies multiple networks of cooperating genes driving intestinal tumorigenesis, Nat. Genet. 43 (2011) 1202–1209.
- [163] H. Takeda, Z. Wei, H. Koso, A.G. Rust, C.C. Yew, M.B. Mann, et al., Transposon mutagenesis identifies genes and evolutionary forces driving gastrointestinal tract tumor progression, Nat. Genet. 47 (2015) 142–150.
- [164] E.A. Bard-Chapeau, A.T. Nguyen, A.G. Rust, A. Sayadi, P. Lee, B.Q. Chua, et al., Transposon mutagenesis identifies genes driving hepatocellular carcinoma in a chronic hepatitis B mouse model, Nat. Genet. 46 (2014) 24–32.
- [165] T. Kodama, E.A. Bard-Chapeau, J.Y. Newberg, M. Kodama, R. Rangel, K. Yoshihara, et al., Two-step forward genetic screen in mice identifies ral GTPase-activating proteins as suppressors of hepatocellular carcinoma, Gastroenterology 151 (2016), e312, 324–337.
- [166] V.W. Keng, A. Villanueva, D.Y. Chiang, A.J. Dupuy, B.J. Ryan, I. Matise, et al., A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma, Nat. Biotechnol. 27 (2009) 264–274.
- [167] L.M. Heltemes-Harris, J.D. Larson, T.K. Starr, G.K. Hubbard, A.L. Sarver, D.A. Largaespada, et al., Sleeping Beauty transposon screen identifies signaling modules that cooperate with STAT5 activation to induce B-cell acute lymphoblastic leukemia, Oncogene 35 (2016) 3454–3464.
- [168] J. de la Rosa, J. Weber, M.J. Friedrich, Y. Li, L. Rad, H. Ponstingl, et al., A singlecopy Sleeping Beauty transposon mutagenesis screen identifies new PTENcooperating tumor suppressor genes, Nat. Genet. 49 (2017) 730–741.
- [169] N.A. Temiz, B.S. Moriarity, N.K. Wolf, J.D. Riordan, A.J. Dupuy, D.A. Largaespada, et al., RNA sequencing of Sleeping Beauty transposoninduced tumors detects transposon-RNA fusions in forward genetic cancer screens, Genome Res. 26 (2016) 119–129.
- [170] P.A. Perez-Mancera, A.G. Rust, L. van der Weyden, G. Kristiansen, A. Li, A.L. Sarver, et al., The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma, Nature 486 (2012) 266–270.

- [171] K.M. Mann, J.M. Ward, C.C. Yew, A. Kovochich, D.W. Dawson, M.A. Black, et al., Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma, Proc. Natl. Acad. Sci. U. S. A. 109 (2012) 5934–5941.
- [172] Z. Zhou, A. Flesken-Nikitin, D.C. Corney, W. Wang, D.W. Goodrich, P. Roy-Burman, et al., Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer, Cancer Res. 66 (2006) 7889–7898.
- [173] Y.W. Asmann, A. Hossain, B.M. Necela, S. Middha, K.R. Kalari, Z. Sun, et al., A novel bioinformatics pipeline for identification and characterization of fusion transcripts in breast cancer and normal cell lines, Nucleic Acids Res. 39 (2011), e100.
- [174] K.C. Ha, E. Lalonde, L. Li, L. Cavallone, R. Natrajan, M.B. Lambros, et al., Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines, BMC Med. Genomics 4 (2011) 75.
- [175] C. Klijn, S. Durinck, E.W. Stawiski, P.M. Haverty, Z. Jiang, H. Liu, et al., A comprehensive transcriptional portrait of human cancer cell lines, Nat. Biotechnol. 33 (2015) 306–312.
- [176] D.R. Robinson, S. Kalyana-Sundaram, Y.M. Wu, S. Shankar, X. Cao, B. Ateeq, et al., Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer, Nat. Med. 17 (2011) 1646–1651.
- [177] P.J. Stephens, D.J. McBride, M.L. Lin, I. Varela, E.D. Pleasance, J.T. Simpson, et al., Complex landscapes of somatic rearrangement in human breast cancer genomes, Nature 462 (2009) 1005–1010.
- [178] H. Edgren, A. Murumagi, S. Kangaspeska, D. Nicorici, V. Hongisto, K. Kleivi, et al., Identification of fusion genes in breast cancer by paired-end RNAsequencing, Genome Biol. 12 (2011), R6.
- [179] L.G. Martelotto, M.R. De Filippo, C.K. Ng, R. Natrajan, L. Fuhrmann, J. Cyrta, et al., Genomic landscape of adenoid cystic carcinoma of the breast, J. Pathol. 237 (2015) 179–189.
- [180] T.M. D'Alfonso, J.M. Mosquera, T.Y. MacDonald, J. Padilla, Y.F. Liu, M.A. Rubin, et al., MYB-NFIB gene fusion in adenoid cystic carcinoma of the breast with special focus paid to the solid variant with basaloid features, Hum. Pathol. 45 (2014) 2270–2280.
- [181] D. Wetterskog, M.A. Lopez-Garcia, M.B. Lambros, R. A'Hern, F.C. Geyer, F. Milanezi, et al., Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers, J. Pathol. 226 (2012) 84–96.
- [182] E.M. Rettig, M. Tan, S. Ling, R. Yonescu, J.A. Bishop, C. Fakhry, et al., MYB rearrangement and clinicopathologic characteristics in head and neck adenoid cystic carcinoma, Laryngoscope 125 (2015) E292–E299.
- [183] Y. Liu, J. Easton, Y. Shao, J. Maciaszek, Z. Wang, M.R. Wilkinson, et al., The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia, Nat. Genet. 49 (2017) 1211–1218.
- [184] V. Frattini, V. Trifonov, J.M. Chan, A. Castano, M. Lia, F. Abate, et al., The integrated landscape of driver genomic alterations in glioblastoma, Nat. Genet. 45 (2013) 1141–1149.
- [185] N. Shah, M. Lankerovich, H. Lee, J.G. Yoon, B. Schroeder, G. Foltz, Exploration of the gene fusion landscape of glioblastoma using transcriptome sequencing and copy number data, BMC Genomics 14 (2013) 818.
- [186] G. Robinson, M. Parker, T.A. Kranenburg, C. Lu, X. Chen, L. Ding, et al., Novel mutations target distinct subgroups of medulloblastoma, Nature 488 (2012) 43–48.
- [187] C.W. Yde, A. Sehested, A. Mateu-Regue, O. Ostrup, D. Scheie, K. Nysom, et al., A new NFIA: RAF1 fusion activating the MAPK pathway in pilocytic astrocytoma, Cancer Genet. 209 (2016) 440–444.
- [188] M.A. Chapman, M.S. Lawrence, J.J. Keats, K. Cibulskis, C. Sougnez, A.C. Schinzel, et al., Initial genome sequencing and analysis of multiple myeloma, Nature 471 (2011) 467–472.
- [189] N. Cancer Genome Atlas, Genomic classification of cutaneous melanoma, Cell 161 (2015) 1681–1696.
- [190] A. Pierron, C. Fernandez, E. Saada, F. Keslair, G. Hery, H. Zattara, et al., HMGA2-NFIB fusion in a pediatric intramuscular lipoma: a novel case of NFIB alteration in a large deep-seated adipocytic tumor, Cancer Genet. Cytogenet. 195 (2009) 66–70.
- [191] B. Dadone, S. Refae, C. Lemarie-Delaunay, L. Bianchini, F. Pedeutour, Molecular cytogenetics of pediatric adipocytic tumors, Cancer Genet. 208 (2015) 469–481.
- [192] M. Lacaria, D. El Demellawy, J. McGowan-Jordan, A rare case of pediatric lipoma with t(9;12)(p22;q14) and evidence of HMGA2-NFIB gene fusion, Cancer Genet. Cytogenet 195 (1) (2009 Nov) 66–70.
- [193] J. Asp, F. Persson, M. Kost-Alimova, G. Stenman, CHCHD7-PLAG1 and TCEA1-PLAG1 gene fusions resulting from cryptic, intrachromosomal 8q rearrangements in pleomorphic salivary gland adenomas, Genes Chromosom. Cancer 45 (2006) 820–828.
- [194] L. Zhou, Y. Wang, C. Ou, Z. Lin, J. Wang, H. Liu, et al., microRNA-365-targeted nuclear factor I/B transcriptionally represses cyclin-dependent kinase 6 and 4 to inhibit the progression of cutaneous squamous cell carcinoma, Int. J. Biochem. Cell Biol. 65 (2015) 182–191.
- [195] M. Zhou, L. Zhou, L. Zheng, L. Guo, Y. Wang, H. Liu, et al., miR-365 promotes cutaneous squamous cell carcinoma (CSCC) through targeting nuclear factor I/B (NFIB), PLoS One 9 (2014), e100620.
- [196] Z.Q. Yang, I. Imoto, A. Pimkhaokham, Y. Shimada, K. Sasaki, M. Oka, et al., A novel amplicon at 9p23-24 in squamous cell carcinoma of the esophagus that lies proximal to GASC1 and harbors NFIB, Jpn. J. Cancer Res. 92 (2001) 423–428.

- [197] A. Fujimoto, Y. Totoki, T. Abe, K.A. Boroevich, F. Hosoda, H.H. Nguyen, et al., Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators, Nat. Genet. 44 (2012) 760–764.
- [198] Q. Zhang, L.Y. Cao, S.J. Cheng, A.M. Zhang, X.S. Jin, Y. Li, p53-induced microRNA-1246 inhibits the cell growth of human hepatocellular carcinoma cells by targeting NFIB, Oncol. Rep. 33 (2015) 1335–1341.
 [199] N. Takaoka, T. Takayama, T. Teratani, T. Sugiyama, S. Mugiya, S. Ozono,
- [199] N. Takaoka, T. Takayama, T. Teratani, T. Sugiyama, S. Mugiya, S. Ozono, Analysis of the regulation of fatty acid binding protein 7 expression in human renal carcinoma cell lines, BMC Mol. Biol. 12 (2011) 31.
- [200] J.S. Lee, J. Xiao, P. Patel, J. Schade, J. Wang, B. Deneen, et al., A novel tumor-promoting role for nuclear factor IA in glioblastomas is mediated through negative regulation of p53, p21, and PA11, Neuro Oncol. 16 (2014) 191–203.
 [201] C.M. Kang, Y.W. Hu, Y. Nie, J.Y. Zhao, S.F. Li, S. Chu, et al., Long non-coding
- [201] C.M. Kang, Y.W. Hu, Y. Nie, J.Y. Zhao, S.F. Li, S. Chu, et al., Long non-coding RNA RP5-833A20.1 inhibits proliferation, metastasis and cell cycle progression by suppressing the expression of NFIA in U251 cells, Mol. Med. Rep. 14 (2016) 5288–5296.
- [2016] J205 2230.
 [202] S. Fujita, T. Ito, T. Mizutani, S. Minoguchi, N. Yamamichi, K. Sakurai, et al., miR-21 Gene expression triggered by AP-1 is sustained through a doublenegative feedback mechanism, J. Mol. Biol. 378 (2008) 492–504.
- [203] J. Zhao, C.R. Qiao, Z. Ding, Y.L. Sheng, X.N. Li, Y. Yang, et al., A novel pathway in NSCLC cells: miR191, targeting NFIA, is induced by chronic hypoxia, and promotes cell proliferation and migration, Mol. Med. Rep. 15 (2017) 1319–1325.
- [204] C.C. Lee, P.H. Chen, K.H. Ho, C.M. Shih, C.H. Cheng, C.W. Lin, et al., The microRNA-302b-inhibited insulin-like growth factor-binding protein 2 signaling pathway induces glioma cell apoptosis by targeting nuclear factor IA, PLoS One 12 (2017), e0173890.
- [205] D. Baek, J. Villen, C. Shin, F.D. Camargo, S.P. Gygi, D.P. Bartel, The impact of microRNAs on protein output, Nature 455 (2008) 64–71.

- [206] J. Silber, D.A. Lim, C. Petritsch, A.I. Persson, A.K. Maunakea, M. Yu, et al., miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells, BMC Med. 6 (2008) 14.
- [207] S.K. Singh, K.M. Wilczynska, A. Grzybowski, J. Yester, B. Osrah, L. Bryan, et al., The unique transcriptional activation domain of nuclear factor-I-X3 is critical to specifically induce marker gene expression in astrocytes, J. Biol. Chem. 286 (2011) 7315–7326.
- [208] P.V. Hornbeck, B. Zhang, B. Murray, J.M. Kornhauser, V. Latham, E. Skrzypek, et al., 2014: mutations, PTMs and recalibrations, Nucleic Acids Res. 43 (2015) D512–D520.
- [209] E. Cerami, J. Gao, U. Dogrusoz, B.E. Gross, S.O. Sumer, B.A. Aksoy, et al., The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data, Cancer Discov. 2 (2012) 401–404.
- [210] J. Gao, B.A. Aksoy, U. Dogrusoz, G. Dresdner, B. Gross, S.O. Sumer, et al., Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal, Sci. Signal. 6 (2013), pl1.
- [211] S.A. Forbes, D. Beare, P. Gunasekaran, K. Leung, N. Bindal, H. Boutselakis, et al., COSMIC: exploring the world's knowledge of somatic mutations in human cancer, Nucleic Acids Res. 43 (2015) D805–D811.
- [212] P.A. Northcott, I. Buchhalter, A.S. Morrissy, V. Hovestadt, J. Weischenfeldt, T. Ehrenberger, et al., The whole-genome landscape of medulloblastoma subtypes, Nature 547 (2017) 311–317.
- [213] M. Namihira, J. Kohyama, K. Semi, T. Sanosaka, B. Deneen, T. Taga, et al., Committed neuronal precursors confer astrocytic potential on residual neural precursor cells, Dev. Cell 16 (2009) 245–255.
 [214] J. Harrow, A. Frankish, J.M. Gonzalez, E. Tapanari, M. Diekhans, F. Kokocinski,
- [214] J. Harrow, A. Frankish, J.M. Gonzalez, E. Tapanari, M. Diekhans, F. Kokocinski, et al., GENCODE: the reference human genome annotation for the ENCODE Project, Genome Res. 22 (2012) 1760–1774.